2022-09-30-accounts

The British Society for Haematology (Limited by guarantee) Trustees, report and consolidated financial statements Registered Company No., 02645706 Registered Chai'ity No: 100573 5 Year ended 30 September 2022

The Brit5sI) Sotiety for Haematology (Limited by guarantee) Tru5tee5 J'¢PQtrt CQD$olidited fingncinl st•temertts YÈAr Ènded 30 Séptembej. 2012 Tn￿tees, repoil and adminstralive details Independent auditors, report to the Inembers of The British Society for Haematology (Lllnited by guarantee) Consolidated statement of financial actÉvitIe5 (incorporating an income and expetiditUiE account) Consol?dated bala￿Ce sheet 15 18 19 Coillpany balance slieet Consolidated Statement of Cash-tlows 20 21 Notes 22

The Briti$li SocT¢ty lor HaemAtology (Limitcd by guRI'2llteel Trustee5' I'eport aiid tonsolid#t¢d fiiiancial 51a¢ements Yeftr ended 30 SepteNibvr 2012 The Trustees preseiittheirannual i'eport and the Consolidated audited financial statements forthe yearended 30 September 2022. These financial statements comply with CUlTent statutory require￿entS wid with the requu'ements of the ch￿'Ity'S governing document and with the Statement of Recommended Pizctice-"Ace0wit￿g and Reporting by Charities" Ob eciiwts uiidAclivilies The objects of the Society, which is a Irgistered chai'ity aiid company liniited by guai'£)ntee, ar¢"lo adyance the praclice alld study of haematology and to facilitate contact between persons i]itei'ested in haetnatology" The chief ways in which the Society pursues these objects are through its joumals; tlie pi'oduction of ¢linical guidelines. its Aru)ual Scientific Meeting.. its pl.0￿arnme and educ&tioiial meetings and othej. iesources. The Trustees ¢onfimJ they have refetted to tbe guidance fi'om the Chai'ity Coinmission on publio beDefit and complied with the duty in Section 17 of the Charitie5 Act 2011 to have due regai'd to the CommTsgioll'8 public benefit guidance. The Trustees confll'm that they have refen'ed to the gusdatjce contoiued u] the Charity Commission's general guidance on public benefit when ieviewing the Society's aiins and objectives and iu plantiing futh&re activities, The Society's new Mission StateM￿)t places due emphasis on public benefit, beginiiing witli this sentence.. 'BSH pi'omotes excellence ii) the study, research and pi2ctice of haeinatology for the benefit of professionals and the widei. public" Déiqll eoiif A¢iivitie5 The Society Id￿nched its new strategic plaii, LISIe￿ing, Le￿niNg, Leuding, Febrvary 2021. The cun'ent strategy's Vssion and Mission Stateinents are.. Vision. BSH will be the Enembei'ship organisation of first choice for all UK h&t￿4t010gY PiDfessionals, an association through which they eonn¢cl. shaTr thell. leai'ning alld provide a highly influential voice all aspe¢ts of haeinatology. h4i&si BSH pi'OTngt¢s excellence in the study* rese￿.¢h, and practice of haEniatology for the benefit of professtonals &nd the widei. publi¢. The chief ways that BSH acts on its mission are.. l. providitig and sllpporliEI8 multi-disciplinary education for s￿dentS and piDfes5ionals at all levels- raisllig standards of cliiiic41 cal'e and laboratory pi2G(iLe throu¥h guidelines and the provision of expert advice., 3. providing suppojt for resewth via its publi￿ti￿ns, pru¥ramrnes and gi'ants providing netwoj'king oppoi1uNities that brin¥ h£t¢llkalology pix)fes$ionals together. i'epre8tnting the interests and ¢oncems of hit¢rndtulugy prufe5sioiials at national and international levels There are three stt'ategic ain)5 for the three-yeai. lifetime of the plan: Member311ip support for all MDT professionals lcmowledge transfer 3. AdV0￿¢Y for baemalology alld its professionals. In the plan, th¢ So¢i¢ty 8150 ￿mMitted to making progress ott EDI and Bnviron]nenlal concerns. The plan is being followed up every 3ix months with an Update to the Board on pi'ogress made. Significant a¢¢ivities were.. ASM ai)d other eduutional events Pi"ovisioll ofthe Bi'ilish Journ¢71 ofH¢Teinalolog), (BJHaem) ￿ld the open acoess joui'nal alHa£m- Grant-illakllig progi'amme. ClllJicAI Guidelittes. Membership,. Advocacy woyk. We report on these items in mole delail below. Re8lSteted cornpany number.. 02645706

Tllc Brit15h Society for Haemaéology (Liinited by guarantcol Ti'uslees report Rnd consolid%ted finaijf iAI stiteintii15 year ended 30 September 2022 Aiithual Scientifie Meetiiig (ASM) The 2022 BSH ASM was held as a hybi'id ￿eetIng fiDTn Mancliesloi. Central froin 2-5 April, with the Pitfalls s¢ssions on Saturday l April. This was ai)othei' successful ]neetiiig with 1,535 delegates (1,057 attended in person and 478 virtually). R6gistration tremained open after the Ineeting to allow delegates who tnis&ed the live meeting to view the On Demand content libi'aiy, which was available until July 2022. The ASM coTrttibuted to Ilie subsidiaiy InakÈng a profst of £155,175 for the year. In spring 2022 BSH began a tender process for th¢ PCO contract, as exercise in good practice, aTLd CPI was awarded the contract for a thi'ee-year pei'iod with a on¢-year break clause. Education and owareness Overall, tl)e BSH $pent £1,134,L175 on education and awai'tness activities compared with £992,693 in 2021. Durillg tlie year the Society contributed £5,000 as sponsorship of the Annual Sickle Cell & T]ialassaemia (ASCAT) event (2021., £29,167) as well as sponsoring tbe RCPath Suininer School witl) £1,500 (2021.. £1,500). Tlie pandemic eontlllued to dictate tl)8t educatio￿81 events be deliveyed Vlliually. The Society l)a8 invested £237,552 iii the BSH website duritig the year (2021.. £37,123) BSH provides the BJH¢7eFlI to all ￿11 and fiill (reduced) members at a cost to the Society of £144,918 (2021.. £137,993), BJHoeiii is co-owned by the Society and the publishei. Wiley. The Society and Wiley also co-own an open access joumal, &JHueiN, which has enabled the publicBtion of additional quality inateiial as a valuable overflow fi'om BJHaEin,' the Society received £51,920 in l'oyalties fro￿ aJHueni dui'ing the year. EveRIs The Society ran 3 facc-lo-face and 6 Vlltual education events throughoutthe year, via its Education Committee and Special InteiESt Groups (SIGS). The events wei'e aci'oss a wide iBnge of subje¢t5, and a¢ros5 a variety of audiences, ll)cluding students and trainees. itL71 EdLfca¢ion I'he Education Team (staff and volunteers), via a system of sub-edxtoi's, ensure tbat the website is up to date. The Committee has appix>vcd a nu]nbcr of new case reports and haeillatology Emages for publication on the site. The Committee has al80 wi'ittcn a number of MCQS based on recently published BSH guidelines and good pi'actice papers which have been addcd to thc quc5tion bat)k on tlie website. The review of all educational material published is ongoing. The Society invested £3,790 in a new LeaTning Management System (LMS). Et was intcnded for thc r￿St COUT5e on tralis￿s1On, designed by volunteers on the Education Cot))mittee, to go live in spring 2022. Howev6r, due to technical issues, the launch was postponed lo 2023. Grants, &ivards and prize5 The categoi'ies of awai'ds are as follows.. Grant name Total avgilable era iicant sMdent Elective Scholarships Tizvel Scholanhi American Society of Heinatology Travel SGholarshi 20 awards per amnum 8 awards er al￿￿1n 3 uwards per annum n)&xEmum £1 000 licant maxin)um £1 000 era licant n)aximum $2.000 per applicant era Ellvopean Hematology AssacEation Travel Seholarshi ai'l -sta e Research Stait-u i-ants BSH ASM Travel and Abstt*ct Scholai'shi Meetin Su oil rants Visitin Fellow Scholarshi Global Haematolo Scholarshi Cohort Study Grant + 10 awards pei. aonuin InaxEmum £500 per oppliunt 10 er a￿U pool of £43,750 available Inaximum £20,000 era licant maximum £ 1,000 pcr applicant 5 awards l aw81'd ear l award per annum e¥ annu £1 000 per applica￿t maximLrIn £18 000 ei. tt licant aximum £6 000 er a licant Up to £50,000 per year to a total of £150,000 per project ovei. the coui'se of tlu'ee ears MaxÈmum £300 er er Trainee Education Bursaries Pool of £10,000 &Yailable era licant Registered company number,. 02645706

• The fuiids for these awards are fix)m Designated Funds Further infotination on the wants progi'amine is available on the BSH website. The Research and Grants Coinmittee oveTseEs the grant applications, Inakes tlie aw￿'dS and Yepoits back regularly to tl)e Trustee Board. The Board Sets the gTant-Inakiti8 stFalegy foi. the SocE¢ty. (See also the section on Designated Funds, witl) refei'ence to the Data Registry Fund). Last yeai" the Boai.d desigtiated £1SOk to assist the Covid VaccinÉttion Fundillg Collaborative led by Blood C8ncer UK. The project caTTied out research into efficacy of covid vaccine for people with blood cancer and duvitig tile y¢ar £97,602 has been conh'ibuted lo th¢ PlDject. This is repoi1ed in Note 6. At the eiid of tlie year £79,619 woi1h of scientific gi'ants had been awai'ded compared with £233,052 in 2021 (see Note 6). A total of 42 grants weir awarded compared with 20 in 2021 and 30 in 2020. With travcl restrictioE]s being eased dui'ing tlie yeai., Ivore thavel-related gi'ants were able to be awaiyled. howevei. th¢ie has beett a deciEase Early-stage Resear¢h (ESR) awards with £1.969 in 2022 compared to £162,323 in 2021 (the 2022 figure dÉsclosed in note 6 being an undei'_payment adjustmellt). Tliis was due to the ESR award5 being put on hold whilst an exte]￿al review was ulldertakeii. BSFI eoiitinued with the National Institute for Health Research (NIHR) - BSH"Researcher of the Year" awards in 2022. Thi'ee award was made this year, to consultant Toby Eyir, trainee lennifer vid1￿. and AHP Paul mcLau￿]Il￿, who i'eceived the1￿ awards durRng the Presidential sessioii at the ASM. The theIne for the 2022 C￿cIble Prize wRs'WhAt eurront Iiaematology praetlees ivould seem absurd to the ha¢matology communlly iu 20509Y The wini)er was Richard Buka. BSH also awarded Gash prizes to ihe top two entries u) its annual student essay ¢oinpetition to a total value of £750. CliAltal Cuid¢lines The Society's Guidelines Committee and its four Task Foi'ces continued to produoe high quality clinical guidelines whi¢h ot only support the baenialological coinmunity in tbe UK but are used woi'ldwidc. Ilie CTuideline$ ConunitteE has also provided haematological advice lo the National Insti￿te for Health and Clini¢al Exc¢ll¢n¢¢ (NICE). Th6 costofthr production of guidelities was £25,394, which included £15,721 spenton lit¢rature searches {2021'. £43,960) and £9,098 spent OII Tecording of audio ￿mIlIe1)tarIes. The Society has continued to pi'odu¢e Good Practice Papers and Position Papcrs in additian to the full Guidelines. The Society publxshed its r￿St Position Papei. in January 2020, Red blood cell siiccifications for Pcitients with h&emoglobinopathies,' a syste￿atiC review and guidelu)e" The Society produced ten Guidelwes, seven Good Piactice Paper (GPPS), and one addenda during the yeai.. M&ny of tli¢ recently published guidelines Iiave a written commentary (published in the BJHaéiii) ond audio commentary (podcasts). Litd(s to the audio coninientaries al'e available on the BSH website and oll PodBean. Fron) laniiary 2021 tile audio cominentai'ies al'e available to dowi)load, The Guidelines. GPPS and addenda issued weiE'. General Haem Task Force Good Prnctic¢ Pa er on the Use of next- eneration se uencin itj the dia n08is of con enital anaeinias joint guideline wath EHA atid joint publishing in BJH and Hemaspheie Publi8hcd 6 June 2022 Guidelilles on the Laboi?to Dia osis of Malaria {Published 10 Mai'cli 2022) (audil wi'itten) Guidelines foi. the monitorin and inaDa einent of ll'on overload in atient.% with haemo lobiiio alla6mias (Published 6 Oct 2021) (audit wi'itten) (Podcast publish¢d) Good Practice Pa ei. on tlie Labo¥atoi dia nosis of ll.on deficienc childi'en (Published 21 Oct 2021} (audit wi'itten) Guidelines on the diagnosis and treatment of adult aplastic atkaemia (8ubtnitted foi. publishing 6 Aug 221 Haem-oac Task Force athies and i?re du1É5 excludiii an and GPP Mana ement ofold￿. Patiemts with frail atjd AC￿te M eloid Leukemia (Published 24 August 22) Good Practice Pa ei.: Recommendatiot]s for Labora¢oi testtn of atients with Acute M eloid Leukaemia in the UIC (Published 27 Oet 221 Addendum for Guideline for the ma]ia emeiit of mantle cell I homa (Publi51ied 28 July 22)
• Guidelllie for the Tieatment of chroiiic I In hoc tic leukaemia {Published 21 Mai. 2022) Guidelines oll Mana Inent Wftldenstrom's macix) lobulina¢mia (Publfft51ied 12 Jan 2022, podcast available) R¢gÉslered COTnpany nutnbET'. 02645706

Th¢ Brit15h Society for Haem%tology (Limited by gu%rAnteel Trustees, report And eonsolldAted (InathtSAI stttttments Year ended 30 Septenjber 2022 6. Guidelll)e FllBt Line Ma ent of Classical Hod kins L Dia ll05is and mana eiit of mature T-cell and NK-cell m811 7. (Published 23 Nov 2021, podcast available) (audit wi"itten) 8. Guidelines on M8n? e ent of Cai.diovascular Com lications ofBruton's T 'osirte Icinase i hibitor BTKI ther8 in Chronic L ic Leukaeinia CLL Patients (Published 8 Sept 2021, podcast availabl¢) (audit wi'itten) 9. GPP Ri ter Tr (audit wi'itt¢M) lloitta (Published 22 Feb 2022) Guidelines on ancies tt8foiThation of ChronÉc L In ho¢ ic Leukaemia (Published 4 OcE2021, podcast available) FI&T Task ForcE Guidelines foi. Th]'oinbo lillia testÈn (l)ublished 29 May 2022) Addendum on Guidelines on Ihe Peri-o ei'ative mana ement of allticoa (Published 27 Fcb 2022) 3. Good Practice Pa eronthe uidattce for Haematolo ical investi ossible sical nialtrettttnent Published 28 Jul 2022 ulation and anti ltttelet theia ations within child rotectiots itiV65ti ation of TranS￿s1o]I Task Force d Practice Pa er.. Pre-o podcast) (audit wi'itten) eline the haematolo rdtive atient blood mana ement durin the SARS-CoV-2 andemic (with ical mana ement of ma or haeinO￿la ublished 10 June 2022 Tl)e Guideline5 Task Forces have also collaborated with the Education Committee, which h9$ written MCQS for the following guidelines.. Guidelines on the use or irradialed blood Lompunents (3 qu¢stion$) Management of cai'diovascular coinplications of Bi'uton tyrosine kinase irthibilors (2 questioms) The management of Castleman disease (2 questiL)ns) Guidelin¢s for diagnosis and management of hairy cell leukaetnia (HCL) and hall. cell Yariant (HCL-V) (I question) Guidelines for the diagnosis and evaluation of prognosis of adult n]yelodysplastic syndrornes {2 questions) Fi'ontlinc managcn)ent of post-transplan(ation lymphoprotiferative disorder tn adult solid oi'gan retipient paticnts (6 qucstions} The Society, as pait of its str4tegy, has matntained the guid¢lines programme budget for literature se&rches' and the budget for other services pi'ovided by medical wiiters. Througliout the pandemic, tbe Gutdelines Committee has woyked hai'd to provide valuable general and specific ha¢Ma￿logical up-to-date lliformation on Covid.19. With the positive development of the vaecllies there is a statement o lh¢ BSH website ofi vacclliation at]d inimunisation that has been rcviewed at]d ag]eed by tlie RCP at]d RCPath. This has proved useful for health care prtkfrssionals aiid to patients. Further details can bt found 011 the BSH COVID-19 u dates page on the website. The informatEon is Jtgtslarly reviewed a¢Jd updated. Membership Four hundred and ninely-three new members joined the So¢iety in the financial year Ending 2022 compai'ed with 577 in fmancial yeai. ending 2021. The long-term impact of the c05t-of-living ¢risis and Wo￿[01.(¢5 issues is not yet known, and whilst moir rnernbei's are joinin8 than leaving, the SocÉety is not ¢ompla¢¢nt. One hundi'ed and twelve niertlbei's left the Society ID 2022 compared to 168 in 2021. Register￿ company number., 02645706

TIL¢ British Soeffiety foi. HaoinRtology (Limited by guai'finteel Trustees, Yeptsi't co￿5￿]1￿￿ted finfinci41 statements Y¢Rr endeil 30 Septenjbei. 2022 Commllnietstion Our reach via social media, ¢-b￿llet11)S ai)d oui. web5its contiiiue to grow. Oui. Inost populaT socÉal Inedia channel is Twitterwhieh has ￿QWE) from 12,000 followers last year to 14,032. All oui. social niedia accouiits have eJ)gagemeiit from botli liaematology profrssionals ajid patÈents from around the world. BSH has a 17nge of e-bullelin& that Mel￿berS and non-lnembers catt 8ibm UP to, the Fnost popular, at the time of wi'itÉn& being.. Guidelines, 6,727 subscribei Ev¢nts 5,313 subscribei's Grants 4,555 subscribers Member-only, 1905 subscrib￿¥ Our open l'ates aveiage, at 420/0, is well aix)ve the industry avei'age (23.42. %). Our website has had over 531,962 page- views, with the Guidelines continuing to be the mostpopular pag¢ {45,917 views). Website users co1￿¢ from 188 diff￿￿1 countries which demonsts?tes our global reach. Our new cookies policy means trackinE website Eisers via Google analytics ts no longei. so accui?te in tei'ms of nuillber of page view8 as most people who use the website do not opt in to being tracked, though we cai) still see which pages are the ]nost populai.. As a result of its previous website company going into liquidation BSH (Ippointed a new website company in November 2021. Lt has Spent Inogt of 2022 tsnboai'ding the new cojnpany and woi.king a major upgrade to the webslte CMS as our current version becomes unsupported in Septeniber 2023. This pi'oject involved re￿.]littg the code foi. tho whole website and migrattng the content and website account fi'om the old website. BSH at 60 In response to the changing circ￿MStanceS caused by the pandemic, the project continued into late 2021 alld was reviewed on a regular basis and i'evised as necessary, to ensure the a¢tivilieb TeEnHin appropriate and expendituit withit] the designated budget of £400,000 remained pi'oportionate. Their were fundb of £44,830 left at the end of th6 project, and this bas been tsansfeired to the General Fund to be pllt towaids th¢ Early Careers Forttm. Advocacy The 2019 BSH Workforce Report, plus the 2020 membei'ship suivey hib,hlibhi¢d the illClEa5ed pressures on the enliiE l￿emato10gY workforce and workforce issues were seen as a Inajor conLell) foi. the membership. BSH is gtt the beginning of a large workforce project, and are cutr6ntly tendering for a partner organisation to help it look at three a]Eas of the haematology woi'kforce.. Woi*force gap analysis PTrctitionei' wellbeillg Ideiitification of solutions and llnprovetnents. BSH advocate for their InembcrshEp via: Woi'king with other orgattisations, for exainple.. Feeding into an Academy of Medical Royal Colleges repoit on 'Nomialising the Unacceptable, via RCPath, (September 20221 Supportin% the campaigns of the Inequalities in Health Alliance (September 2022) Signing the open letter from the Stirngth in Numbers cainpaign froln RCP. (Noveinber 2022) Supporting social media canpai81)s from oi'ganisation5 such as NHSBT, BCUK, Thrombosis UK and otiier aligned oi'gantsations. Representation at irlevant stakeholder meetings, such a5 tkukaeinia Care I'ouiidtable (Oetober 2022) Engaging with parliaineTktaiy groups 8uch as sponsoring the APPG OD Diversity alld InclusTon in STEM and att¢lld￿g APPG oil Sickle Cell and APPG on blood cancer meetlligs Respoiiding to government Consultations, such as Workforce reCt￿ltMent, training and relerAtion in health and social care (January 21)22) Rc8i51ClEd company nutnbEr.' 02645706

Tli¢ Bi'itish Soci¢ty for HatmatoloEy (Limited by gui'llttel Trustees report Hnd tQ11501idatÈd finAncial statements Yeai. endod 30 SoptembEr 2022 Finaiite The Boai'd will review how more of the reserves I￿ight be used for pi'ojecls in fvIthe￿nCc of tlLE Society's Gharitablc aims and objectives. Infected Blood Inqlllry (IB The Society continues to assist Ihe IBI which is now reviewing the niaterial that the Society i'eleased to it in early 2019. The Officers and CEO have delegated autliority froill the Board to handle the qua'kes iaised by the IBI as and when they ai'ise. Revleip o iiiftiiclnl osllloii The TI￿SteeS al'e satisfjed with the group's I'esults foi. the year which al'e shown in the consolidated statement of finan¢ial activities and income and expenditure account on page 18. The Society has Incu￿ed no ffnallcial Costs in any fundraising activily. Neither did the Society engagE any external fundrais￿.5, nor did it receive any complaints in respect of its ndraising activities. The Finance, Audit aiid Risk Conuhittee (FARC) monitoiE all f￿anCIal aspects of the Society ill¢ludiDg its trading aiin and the investmejits 5tt'ategy and pei.formance. Income The total consolidated inconie for tbe yeai. was £1606,810 (2021., £2,759,399). Our biggest in¢om¢ streaiii remains our share of the profits of ihe Bi'iiish Joiii'nal of Iloemalologv (both BJHaeiiT & Iluwii) whicb was £1,144,432 (2021.. £1,398,034). Dui'ing the year, tlie impact factor of the BJHaein was 8.615- it Cont￿uc5 to appear io the top quartilc of ha¢matology jounmls. The eJHaeM is now in its second year alld continues to grow, with royalties of £51,920 b¢ing paid in rtlatiott to the year ended December 2021. The Society continues to monitor the Joumal fU￿n¢eS and the fore¢ast for this year r¢mains conservative. The succrss of the hybi'id ASM in April 2022 piDduced £1,175,034 of total Èncome. Income from membership subscriptions was £233,868 (2021.. £215.165). witlk an ll)crease in Subs￿]ption i?IBs being irnpl¢mented in January 2022. There were 2,913 active members at the year-elid which represents a net it]CTease of 149 from the previous y¢ar (2,764). ivestment incoine was £52.465 (2021.. £56,668) reflecting both the defensive strategy wilhsn one of the investment portfolios as well as th¢ red￿CtiOn in m￿ket p¢i"fonnances as a wliole. The Society shows divideiids iriiivested in the Investtllent Portfolio as inooille dui'ing the y&qr that it was received. xpeiidature Most restruyces expended were forwnning tht Society, running of the annual conference, educatiojjal services, providtng the 10￿M￿l to inembers and resea1￿h gu7nt5. Grantg al'e i'ecognised iii the Ststement of Financial Activities wl)en tliey are authtri'ised by the Research and Grdnts Committee. See aboye, Significant Activities and Notes 6 and 7 for detailed repoiting on grants and education. The trading subsidiary IEsuIts are discussed below and at Note 9. Designated Funds The work of the Global Haanatology SIG was rea¢tivat¢d having been postp)n¢d duruig 2021. The Pl¢nary Sp¢aker8 scheme was started up agaiE] itk May 2022 with thjee speakers s¢le¢ted to speak at ¢onfeien¢es in Egypt w October 2022, Ghana in Noveinber 2022 and Thailand in Nl8y 2023. Th¢ Global Haematology Seholai'ship was reactivated and two grattts out of the four grants on offer were awarded. The SIG had pieviou$ly linked up with the ASH Sickle Cell New- born Screening programme and pi'ofessiona15 in Zambia the individuals iiivolved remain ill contact and the visit will go ahead in 2023. R¢gI￿¢red comp2ny t)utllbtr.' 02645706

Tljt Briti8h Soeiety for HaeErJ?tDlogy (Limitcd by guarantee) TrustÈÈs' Yeport *rtd £oH501idated fJiianciAI stRtemeats Yeai. ended 30 September 2022 The Wilkinsoti Bequest ¢ontinu¢s to support ilie provisioi) of tl)e Dacie Wilkinson Bequest LECture by ali inteinational speak¢i' at the ASM in coi)junction with tl)e RCPath. Costs associated witli this lecture in 2022 amounted to £120. During the year.. £97,602 has been contt'ibuted to the BCUK Vaccii)e Collaborative. The £150,000 iii the Data Registry Fund has been awarded and 15 being paid out at regulai. i11t￿'Va1s. In 2020, the Board also designated £20k to be spent over two years on regional evejjts and edllcation. The fund was due to roll out dui'ing 2020 with the Researcli and Grants Comtnittee admiiiistering it. However, because of Covid-19 this was placed on hold. No funds have yet been spent. Trading activities The Chai'ity's subsidiary company inade an ovei'all profit for the year of £155,175 (2021.. £575,596) and the results alr shown iTh note 9 to the fjnancial stateinenls. The iesults for 2021 reflect the fact that two tonferellces were held, 8nd both were virtual, as a consequence of the pandemic in 2020. Rescrvcs policy The assets of the Society included tangible f]xed assets £421,263, llJvestmet)ts of £7,848,147, net cunrnt asscts of £2,471,912 and OV￿all the Society's nel assets stand at £10,741,322. This includes desEgndted funds of £149,885 ajid general funds of £10,591,437. During the year total fiillds decreased by £632,915 to £10,741,322. Th¢ FARC continue5 to ￿OnItOr the Chai'ity'5 Reserve Policy annually. The level of the Opa'ational Reserve continues to cover 1.5 yeats of n]nning cost5 should it be necessary to wind down tlie Society for any unanticipated i'ea501) or if futUlE lllco￿e falls. plus ￿￿OUnt5 to cover flu¢￿at]llg ASM su￿luS£S and the unlikely (but if it occunEd, dainaging) drain8tic, unexpected1055 of sponsorship incoine for the ASM. Ali allowallce of 20/ for mai'ket volatility was agrecd, rrsultEng an Operational Resei've f￿Ure of £2,550,000. In addition, there should be a cash i'eserve of £500,000 at the yeai. end to tn8intaTll fluidity,. please see the table below which shows tbe short alld long-term operational reS￿VeS. The Society's investmetjl illw'ket values hav¢ i'E]nained robus¢ during th¢ pandemic period, partly due to the move to a ore dEfensive strategy withitL the Coutts investment portfolio. The Board h￿S asked the FARC to i'eview and make recominendations for use of the Society's surplus reserves. Excluding oper4tional fixed assets, operational reseryes and designated funds, surplus reserves at 30 Septenibei. 2022 al'e £7m. SHORT TERM FUNDS Op¢rntional cash requueinent3 are held in account5 Wlth Coutts and HSBC, as are those foi. BSH Ente4?I'i8es. Shoi1-term IEserves ale hcld in a Coutts R¢serve account. Funds in excess of ¢ashflow re uireinents are eriodi¢all moved to the investment funds. £500K at the y¢ar end LONG TERM FUNDS The Miniinum Reserve is managed as part of InvestJn¢nt Funds by Specialist Investment Managers with same risk pi'ofile as funds I'equÈred in 3-5 yea￿. £2,550,000 TOTAL £3,050,000 Registered company numbet.. 02645706

The Brltlsh Society ftrr HaematDlogy (Limited by guarlljjtee) Truste¢5' report tOliSDlldAt¢d financiRI statemen15 Yeat end¢d 30 Sept¢mbei' 2022 Investme￿t poliey Investments contlliue to be managed according lo the Investtnent Policy agreed in Janualy 2019 attd the FARC ffis due to ndei'take a review ON thi5 policy in 2022 as part of a wEda' IEview of the yortfolios. The Trust¢¢5 have wntinued to take advice from the Society's investment m&nagers to ellsure tl)at the illvestmentportfolio is managed in line with its ethical i'equirements and spread lo i'educe risk to the Society. To this end, the Society's CCLA investment fuiid was trallsferred to th¢ir Ethical Fund in July 2021 tt'iggerillg & realised gain on investments of £507,416. Th¢ overall investnienls inarket v&lue inciEased by £1,557,266 in the yeai. (2020.. £380,050 decrease} aild this trdkes into account tlie £900,000 injection of funds into the CCLA portfolio ID September 2021 as well as realised gains in the year. The portfolios ar¢ aun¢d at growth in value i'atl)er than income g¢u¢ration, with incoll)e being i'einvested. The total iT)vestment portfolio was valu¢d at £7,848,046 as at 30 September 2022, compai'ed with £8,579,192 in 2021. Investment incoille wa& £52.465, COEnpaiEd with £56,668 in 2021, with dividend8 received and being i'einvested within th¢ investtnent portfolio being shown as incoD]e the year. The maDageis al'e adhering to the r¢stt'LCtions itnposed by the Ti'ustees regarding ethical stai)dai'ds. The prO￿tS￿ of the iMvesth)ents is h?oked and I'eviewed i'egularly. The T]7]5tees have taken advice fi'oiyj the ll)vestment managers and have invested lll a range of direct investtnents alld managed funds which tlleet their llivestment ¢iiteii&. Regular perfonllance reports arereceivcd, and the investment 15 i'eviewed on aregular basi8 by the fARC and bythe Boairf,. during the yeai., the I,'AKL asked both CCLA aTrd Coutts to give a sub51anlive update at its meetillg in January 2021. The Coutts Investment fund is defensive. the CCLA one is highcr E'ssk. Whilst the Truslees al'e not coiiiplac¢nt, they are confident ihat the Society's substantial reserves will be enough to see the orgaiiisalion tkn'ough ihis di￿lcult lime. Investment powers The Tjustees haye thepowerto invest fi]nds not immedi&tely required foi'operational purposes ID such concerns, secui'ities or property as they think fIt. Principal risks 2Trd uncertainties Je Trustees assessed the Society's risk tegiater and the Darectors of BSH Bnteipises Ltd assessed its risk regÉster in September 2021, fhis exercise is undertaken on an annual basi5 in accordance with theguidelines fur chariti¢5. Following the assessments, bo¢h documuilswere revI￿d and updated. TheTI'ustees of tlie Society and Direclvrb ufBSH Ei)leryTiS2S Ltd believe they have taken enough steps to Initig&ts ftie rtsks ideiitified for each organisation. The principal i'isk5 that the Society faces, as identified in the updated risk register, are: Failure to trnn51ate stt'ategy into achievable and mea$￿'able activities Failui'e to ensure that the new structures withiii BSH work togethei. effectively: Major IT Systems failure inclUd￿e failure of extemal 5uppliErs. PotentEal ftt)ancial losses, sn particular from trading Sllbsidiary dtte to drop in &'evenue fiDin delegate5 at or sponsoiship of the ASM. Below, we highlight the mitigation woi'k to these risks. The Society is following its current strategic objectives- suppoi'ting members,. knowledge transfer and advoca¢y- witb The Board receiving updates on the progi'ess of the strategy twice a year, so it cai) monitor effeetively. The fociis on advocacy with a particulai. focu5 on work force is a new ai'ea foi. BSFI andmiich of its efforts al'e on building solid foiindations it] order to better support the haematology WO￿ force. A major pi'oject on work force is just about to launch at the time of writing. The S(Kiety is focused on ensiiring that structui'e (the two Boards, Committees and SIGS) resoEirces (staff, building and inoney) are used optimally to ensuiE that the strategic plaTI will be achievable and will enhanee the chai'ity's auns and objectives. The Society office team is now woi.king ￿ a hybrid forniat with time ill the otTice and work from hoine continuing from the height of the Covid-19 palldemic. This has allowed for new ideas and ways ofwoi'king to flourish. Registered cotnpany nutTrbEr.' 02645706

The British Society for IIAemThtology (Limited by 2u#r•rtt¢tl Tr¥stees' report and eonsolid%ted finaneiAI stAtcrticnts Yeav eMderf 30 Stptombor 2022 BSH continues to work oi) impi'oveinents to its ICT lnfi.astt￿ctUre, e.g., nioving from a physÉcal to MS Teaills phoi)e systein. The SocRety lias just completed an upgrade to the content management system to ensure that the system reinains supported and stable iiito the next few years and has just migixted to a new hosting solution. The Society has recently igrated to SharePoint wliich is a elolld-baged system and will illcr&￿e IT se¢uJ'ity. The SocÉety began, in suminei. 2020, to update its Dithstsr Recovery Plan with a particular focus Oll IT systems failures. This was completed and sigDed off by tbe Board in inid-2021, just ahead of the cun'ent fjnancial year. The ch2trity reinains & necessary source of edueation and suppoit for the haematology profession and material losses i Inembei'5' sllbscriptioas are not anticipated following the pandemic. T]ie levels of subscriptions received in Januaiy 2023 W￿.£ consistent with lev61s in previous years, and there have not beei) substaThtial ¢an¢ellations and requests for itfundg during the pandemic. Jolin Wiley & Sons I'egulai'ly update the Society on the fEnances of the Joumals. The production of digital matei'Éal wa8 Possible t]ll'oughout the pandeTnic, and, after a short peTiod of being ui)able to produce pi'tnted joumals immediately following the onset of the pandemic, Wiley was able to i'eeommence the printing process itL eai'ly sun]mer 2020. The 2022 ASM was hybrid, with a face-to-face meeting ii) M&nchestei' and & tonsideiable onltne element. Despite the dditional costs of the hybrid elemenl, thanks to Careful blldgetitjg and yupport fi'om industy, the meeting genei'ated a pIDfit of £155,175. During the year BSH re-tendered its PCO conts?ct and appointed CPI for a period of thi'ee years with a break clause after the first year. VAT The Sooiety continues to Inonitor its VAT $tatus with the assistgn¢e of its advisers and Inanagement accountant. SKnieiii*È The ¢harity is an iti¢orporat¢d legal entity limited by guarantee, th¢ business of whicl) is governed by a Board of Trustees, which m¢ets quarterly. 'rhe charity has 14 FfE staff memb¢r5' this numb¢r In¢l￿deS son]e teinpoi?iy staff and it is tlie Society's plan, wherE ppropriatc, to make these i'oles pcnnallent in the next year. The Trustees have d¢legaÉed day to day responsibility for thc i'unning of the ehai'ity to thc Chicf Executive. ecia1lni￿.etsI Givti SIGS nd oihei. 'oii The Society's six SIGS.. Global Haeniatology,. Laboratory. Lymphoma; Obstetrics,. Paediatric,. and Teenage 2tnd Young Adults (TYA) ￿'e all active ill their ai'ea, undertaking educatioiial work it) various ways. The Society algo has an Early Careers Foruni which is making excellent progress on the pilotillg of a mentoring scheme. The designated Regional Events Fund, which replaced the regional lead structure, has been on liold but the Board will review this in 2023. The ehai'ity has ll)vested £2 in a wholly owned ti'ading subsidiaiy BSH Enteipi'ises Limited (BSHE.) througli which the organisation of the Annual Scientific Meeting IASM) foi. the British Society for HEteinatology is coiidllcted. 'fhe coinpany, BSHF, Ltd. gift aids its taxable profits to the charity. The Trustees of th¢ charity and the DiTe¢tors of the subsidiary al'e i'esponsible for strategic directiot) and govei'nance of the BSH and BSHE Ltd. The Key Maliagement Pe¥soT)nel of the group comprises the Tiustees l Directors ttnd the CEO. No Th'ustees w¢i'e Ten)unei'ated during the year (2021.. nil). Total remuneration to the Key M&nagement Personnel was £74,144 (2021.. £73,837). The pay of the Key Nlanagement Pei'sonllel is reviewed annually. In view of the nat￿l'C of the charity, the Trustees benchmai'k against pay levels in othei. chai'ities. The remuneration settll)g policy is the Inid-point of the l'ange paid for similar roles similar-sized charities. R¢gi5t¢r¢d ¢ompgny nuFnber: 02(A5706

The Bi'itL8h So¢iety for HAemAtology (Limiteil by guiirantetl Trustees, Yeport Ind ¢on501idated financial sta*em¢ntS YeAr Èndtd 30 Septemb¢r 2022 Appointment of trusteesldirectors Ele¢ted TI￿Stees1D¢recÉQrS al'e appointedby secret ballot of eligible inembers during Febl￿ary-Ma1eh ea¢h year,. Oi'dinary Ti'ustees, the SecretRry andtlie Tftasurei. slt fora tlll'ee-year te]Th aijd the Vi¢e-Presidentsei'ves two yeaiB before becoming Pjesident and sei'ving a further two yefti's. Ordinaiy Tiiistees, the Secretary and Treasui'er may stand for el¢ction for a second three-yeai. temi, theiyby enabling them to serve up to six years on the Board in this role. Following a Gene]31 Meeting Èn Septemba. 2020, Tyttstees now take uplrelinqthish office at end of the At)nual Succession Boai'd Meeting, wheJE pirviously this occuntd ttt the Trnstees, Meet￿llE held dursng the ASM. U71is amendment allow$ th¢ Board to appoint new Trustees even if the ASM is cancelled or postponed in future years. The Board has the powei. to eo-opt Lay Trustees; at the time of wi'lting, th￿'e are Iwo (capacity is foul.). The Board is i'ecruiting two additional trnstees in spring 2023. Th¢ Society provides new Tiustees with an induction and guidance fi'om tli¢ Charfftties Commission and othei. relevant publications. Trttstees, reMunet2tiO￿ and expenses are d6tailed it] note I I to the flliancial statements. Political and charltable eoiiti'ibutlons The giDup cannot inake political conh'ibutions under their governing docllments and charity law. The group has ootmade ai)y chw'itable dottattons during the year. rulure Plftrts Strategic Direction The dyee CUiTent strategic aim5 are.. supporting membership and the wider profession; education and learning. and dvocacy for both the profesgion at]d the discipline of haematology. The Society will work towards lauiiching a new strategic plan in January 2024. This will build on the excellent foundations of current aims and plans and in paiticular, will fvtther develop oui. woi'k advocaby lor the haematology woi'kforce aild our digital learning offei'ing. Wc will review the concept of further paitnerships with the biomedical and pharmaceutical uidusty e.g., via annllal sponsorship. The Soeiety will take due ¢onsideration orth¢ likely mediuin to long-temi consequences of Covid-19, economit and oth¢r Inajoi. exteinal financial and geo-political factors on BSH ovei. tlie lifettine of the new stt'ategic plan. Goveriianee and infrastructure A plan for fi1rth￿. wideniDg the sktlls set of the Board is to reen]it two additional Lay Trustees, which w511 happen in spi'in£ 2023. The Society is looking for Lay Trustees witl) skills and experience it) govei'nance, strAtegtG plaDning, EDI and sust&inability. It also wishes to appoint two exlemal B Dtrectoi's to the th'ading subsidiary, BS14E. The Society continues to work on ensurllig that all its constituent parts.. Boards, Committees, SIGS and staff, are woi'king together and following the organisation's strategic dll'ection. Finance The Boai'd will be collsideiing the futuiE use of SUTplus reserves. it is tbe illtention to set up a tmsk and flliish ￿'0uP to obtain external adviee and feedback to the board regarding poteutial options. The Trnstees are awai'e of the potential drops ill inyesttnent income goii)g forwai'd but have confidei)ce that die level income will be maintained ovel. the short to n)edium term. Despite the Covid-19 pandemic and other ecoiiomic shocks in the past yeai., the journals liave coiilinued to do very well finftncially. Lik¢ tnany othei. compallies, the joumals publishers, Wiley, contitlUeS to assess scenarios as tlie glob&l sitsjation evolves in ol'der to be prepai'ed to adapt quickly. Should the Society's income drop substantially tkn'ough this pe1.1￿ it has the reserves to support Costs going fonvaixl for 1.5 years and is ultimately cojitrol of many of tlie material ¢osts. 10 R¢gistered company number.. 02645706

Tkne Britl5h Society far H2eniRtology {Limited by guArArttetl TrustrT5 repoi't tOlls01idAted financiAI st2tements Y&qr ended 30 Stpttmbir 2022 ASM At the time of writimg the 2023 meeting will go ahead as a face-to-face event, taking place in Bimiingham between 23- 25 Api'il. Tlie ProgramiM¢ ComTnittee, tlie BSH Tj'ustees, BSIIE Dii'ectors and senior staff are planiiing future ASMS on a rolling cycle Icun'ently tlirough to 2025, with planning about to begin for 2026) in order to secure attractive venues able to aCCOmTnodaic an expanding ASM. whilst maiiitall)illg a close view of tlie medium to long-terni effects of tlie COVID- 19 pandeinic and oth¢i' I'ecent economic and geo-political factoi's. Membership OUT membership ¢onlinues to grow. especially the ASS(￿late membeiEhip category, with more nurses joining the Society and beimg actively engaged in its govei'nance with representation on most of our Cal￿nitte¢s. BSH will continue to invest i]1 the meiube13hip package with a focus on improvllig the bei)efits including edllcatioji with free webinai's for Énember&, as well as advocacy work and reviewing our wts programme. Registered company number.. 02645706

Slllleiiienl o Triislees res 0115ibillllES lil res ecto Ilie Triislees. Re orl coiiso1ld￿lefI IINiieirt1slNleiiieiils Tlie Trustees (wlio al'e also Directors of The Britisli Society for Haematology for the puiyoses of coiiipany law) are responsible for pjeparing tl)e Tiustees, Report and the fmancial statements ill accordance with applicable law and United KiiigdoEJi Accounting Standards (United Kingdom Genei'ally Accepted Ac¢oullting Practice}. Compally law requires tlie Trustees to piepaie f]nancial slateillents for each financial ye81. which give a trne and fail. view of the state of affairs of the charitable coinpany aiid the g￿￿up and of the incomingresoui'¢es and application of resouiEes, ill¢luding the income atjd expenditui'e, of the charilable group for that pei'iod. In preparingthese fu]3ncial slat¢ments, tho Trustees aye reqllutd to.. Sele¢t suitable ac¢ounting policies and then apply Ihein consisteiitly,. Observe the methods and pj'inciples in the Chai'ities SORP; Make judgements and estimates diat are reasonable and prudent,. State whdher applicable UK Accounting Staiidards have been followed, subj¢cl to aiiy inaterial depprtUi'¢S disclosed and explained in the financial statements,. Prepai'e the finaiicial statements on the going concern basis unless it is inappropriate to pirsume that the charitabl¢ cOmpa￿Y will continue in business. 11]E Tiust¢es ale iesponsible for kcciilng pioper accounting i"ecoi'ds that disclose with r&asonable accuracy at any tlllle of the f￿antIal position of the cliai'itablc company and group and enable them to ensure that the fmancial statements comply with (lie Companies Act 2006. They are also itsponsible foi. safeguarding the assets of tl)e charitable coinpany and the group alld hence fortakingiEa8onable stcps foi. the pi'evettlion and detection of fraud ai)d oth￿. llYegulariÉies. The Trustees air i'e5P0115iblt foi. the maint¢llance and integrity of the coi'poi"atc and fittancial information included on the charitable company's website. Legiqlation in the UrtEted Kingdom goveniing the weparation and dissemination of fmancial statemBnts may differ fi'om legislation in othei. jurisdictions. In 50 far a5 we al'e aware.. There is no relevattt audit infonnation of which the charitable company gi'oup'5 auditOT is unawai'E; and The Ti'u5tees hdve Idk¥n ￿111 steps that they ought to have taken to inake themselves 8wait of atjy relevant audit infoiynation aTLd to establish that the auditor is aware of that inforniatÈon. 12 Rtgi51ered cojnpany number.. 02645706

The Bri¢i5h Soeiety for Haematology (Limited by Euar%nteel Trustees report and eomsolidated finllneirtl stAteMients Yefir ende¢J JO Septembei. 2022 Re ereiice adniliiislrulloii lil Ol'Fiilllloii The Britisli SoGiety for Haematology wa5 registered with tl)e Cl)arity Coinmission on 7 November 1991 (registered nuinbei. 1005735) and was incorporated as a coinpany limited by 8uaraatEe (registered company numba. 264S706) on 13 September 1991. The coinpany is gov¢med by its Article5 of A550ciation inCOTpoTated on 13 September 1991 alld which were last updated on 28 September 2020. Tru51ee51dir¢ctors The Truste¢stDu'ectoiE who held office dui'tng the year weie as follows.. PITsident Pi'esident Vice Presidei)t Vice Pi'esident TiYasur¢r Secretary Pi'ofessor Adele Fieldtng (Ci'om 19 Api'il 2020) Josl) Wyight (froin 05 Apiil 2¢Y22) Dr Josh Wi'ight (fi'om 19 April 2020) Dr Sue Pavoi'd (from 05 April 20221 Dr John AshciY>ft * (from 18 Api'il 2018, Itappointed 28 Api'il 2021) Dr Jim Seale (froin 30 Maich 2020) Ordin J Tnislees Dr Humayun Ahmad Dr Subama Chaknivoty Dr Kate Cwynarski Mai'k Ethell Dr Fei'gus Jack Di. Murali Kesavaii Di. Fiona Miall Ih. Amit Patel Mi. Huw Rowswell Professoi. John Snowden (froin 30 March 2020) (from 03 April 2019, reappointed 05 April 2022) {fiJ)m 02 December 2021 alld re-6lected 5 Api'il 2022) (fi'om 05 April 2(r22) (from 03 April 2019, (i'esigned 05 April 2022) (fiDm 28 April 2021, resigned 23 February 2023) (froin 05 Api'il 2022) (from 30 March 2020 to 28 October 2021) + (froin 30 Mai'ch 2020) (from 05 Aw'il 2022} Co-o ledL Ti'iistees.. Ms Kate Fielding Mr Tirvor Jones Mr Keith Wai'd* (from 05 Sune 2020) {fi'om 19 April 2016, reappointed ID April 2019, resigned 05 April 2022) (from 05 June 2020} * Membel. of Finance Audit and Risk Cotninittee IFARC) + Dr Amit Patel died in Octobei. 202I. The T￿Stee8 of the ¢liarity con3tityte Dir¢ctoiE foi. the purposes of the Compai)ies Act 2006. R¢gist6r¢d company number,, 02645706

The Britisli So¢iety for l14ematology (Linjited by guarAntee Triistees rBport Rnd consolidated finAnciftl $tateineiJt8 Yellr e￿ded 30 Septembei. 2021 Registered offiee.. 100 White Lion SttEet Finsbury London Nl 9PF Advi$¢rs The Gompaay's pi'inc¥pal advisers are as follows.. Solieitors Bates Wells Bj'aithwaite 10 Queen Street Plo¢e London EC4R IBE Clayden l.aw sl floor. 22840 Banbury Road Oxford OX2 7BY Auditoi'$ H(iysmacintyr¢ LLP 10 Queen Sti'eet Place London EC4R IAG Baiilctrs Coutts & Co 440 The Strand Lviidoii WC2R OQS Investment Advtsers Church, Charity and Local Authority ICCLA) Fund Managers Liinited Senatoi. House, 85 Queen Victoria StlEet Loiidon EC4V 4ET Coutts & Co 440 The Strand London WC2R OQS Audltors Haysrnacintyre LLP liave indicated their willitigAe5S to be reappointed for another teJ￿ and appJY>priate a￿ang￿nents have bBen put place foi. thein to be reappointed as auditors. tn pi'eparing this report, the Tiustees hav6 taken advantage of tlie ￿nall comp3nies' exemptsons Pl￿VIded by section 415A of the Companies Act 2006. By order of the Boai'd Dr A John Ashcroft Trustee and Tre25ure 100 White Lion Street Finsbury London Nl 9PF Date 2510412023 Registered cotnpany llutnbEr.' 02645706

The British S(kciety for Haematology ILimited by guArAnteel Indtpendeiit *uditoY's Yep¢i't YeRr ended 30 Septemb¢r 2022 Imdependent aEtditoi' s report to the members of The Bi'Ètish Society for Haejnatology (Limitcd by guarantee) Opinion We have a￿dited the ftnattcial stateinents of 'fhe British Society for Haematology foi. the year ended 30 SepleTllber 2022 which comprÈse the Statement of Financial Activities, tlie Balance Sheet, the Statetnent of Cash Flows, and iiotes to the fii)ancial statemeEits, including a suminaky of gignifIcant a￿oUnting policie5. The fmancial reporting fiYin¢woi'k that has been applied in theij. pi'epg17tion is applicable law and Unit¢d Kingdom AccounlÉii8 Standards, sncluding Financial Reporting St8]id3rd 102 The FinftKcill/ Réporling Siandoi'd applic(7ble ihe UK Repiiblic of Irela￿d (United Kingdom Generally Accepted Aceountitig Pizctice). lil our opinion, tlie fjiiancial statements.. give a true and fair view of th¢ state of the Ghai'itable company's affairs as &t 30 September 2022 and of tlje charitable compatky's net movemBnt iti funds, including the income and expenditure, for the yeai. then ettded; have beal properly prepared lll accordance wÈlh UDited Kingdoin Generally Accepted Accountiiig Practice,. and have been prepared in accordance wÈth the i'equirements of the Compatties Act 2006. Basis for opinio We conducted our audit in accordance with International Standai'ds on Auditing (Utc) IISAS (UIC)) ai)d appli¢able law. Our responsibilities undeK those standards al'e furthei. described in the Auditor's i'esponsibilitÉes for the audit of the tinancial statements section of oui. repoit. We are independent of the chaiity in accoi'dance wEth the ethical I'equiiyinents that are relevant to ouy audit of the fjnanctal statements in the UK, inrludfftE the FRC'g Etliical Stsndaid, and we have tuifilled our other etl)ical responsibilities in accoi'dance with these requll'ements. We believe that the audit evidviiLe we have obtained is sutricient and appropriate to pi'ovide a basis for ou]. opinion. Conelusioiis relatinE to going eoneern Tn auditiiig the tinaiicial statements, we have collcluded that the lrn$tees' llse of the going concein basis of accounting in the prepaJ?tion of the I'inancial stat￿ne1)t8 is appi'opriate. Bftsed OTh the woi'k we have perfonned, we have not identified any m&teriAI uncertainties i'£lating to events oi. conditions that, individually oi. collectively, may cost signiticatjt doubt on the eharitttble coiiipaiiy's ability to eofitinue as a g(Itng eoneein foi. a period of at least twelve months fn)m when the financial statements are authorised for issue. Oui. i'esponsibtlities and the respoiisibilities of the trustees with respect to going concern are described in the relevant sections ot this report. Other infornjation The trustees are IEsponsible for tl)e other infoimation. The other infomiation comprises the inforniation in¢luded ID the Trustees, Annual Repoi'l. Our opinioi) on the finattcial statements does uot cover tlie other infonnation and. ¢x¢epl lo the extent otherniise explicitly stated in our report, we do not express any fonn of assui'2nce conclusion thereoii. In coiinection with our audit of the fjnanctal statements. oui. I'espongibility is to read the othej. infaimation and, in doing , cottsider whethei. the other it)fonllaÉion is materially imcottsistent with the fJn&iicial stalen)ents or our knowledge obtained it) the audit or otheiwise appeai's to be matei'ia]ly illisst&ted. If we idejitify such tnalei'ial in¢onsistenciES or PPt)i'ent matei'ial misstatetnents, we ale i'equii'ed tts detemll)e whether there is a matel'i￿ inisstatement lli the f￿ancial statemeiit5 01. a material misstatement of the otl)er infonnatiot). If, b8sed on the woi'k we have perfornied, WE conclude that there is a matei'ial mis9tat¢ment of this other infoimation, we al'e required io i'eport that fact. We l)ave nothitis to IH)ort in this Yegard. Oplnfions on olher matters prescribed by the Companles Att 2006 In ou]. opimion, based on the woi'k utjdertaken in the Course of the audit.. the info]Ination givet) the Tn]stees' Aunual Report (which in¢lude5 the sti'ategic report and the dllfCtOTS' report prcpai'Ed for the purpose5 of CDmpally law) for the finaiicial yeaT for which the fll)an¢ial Stat￿nents are pirpared is coiisi5tent with the f￿anCIal stalement5', and tIEe strategic i'eport and tl)e dii'ectors, report included within the Thustees, Ar￿Ual Report have been piEpared in accoi'dance with applicable legal requiremen¢s. Matters on which Ive are req￿￿red to report by exception In the light of the knowledge aDd understanding of the cliai'itable compat)y and its envirotunent obtailled tn the course of the aiidit, we liave tjot Ide￿tIfIcd Inaterial misstatemenls in the Tiustees, AIiE]ual Repoit (which incoi"poi'ates the strategic i'epoit and th6 directors, report). RegisteTed company lluMb￿.. 02645706

The Britisli Society for HaEmRtology (Limitod by guaranteol Ind¢p¢ndent auditor 5 report Yexr tndtd 30 Sept¢mber 2022 We have ttothiiig lo report in rE5PECt of tlie following inatters in relation to which the Coiijpanies Act 2006 reqttÈre5 US to report to you if, in oui. op1￿10n.. ad¢quate accouiiling recoids have not been kept by t]ie charitable cojnpany. oi. the oharitable company financial statenients are not ID agreement with tlie accouiiliug i'eCOTds and rctstrns. or certain disclosures of trustees, i'emuneTation specificd by law are not made. or we have not received all the infoirnation and explanations we requll'e foi. oui. audit., or the trustees were not ¢nlitled to prepai"e the f￿ancIal stateinents aecoi'dance with the sinall companies, ]tgiikn¢ aE)d take advantage of the sihall con)panies' exeittptions in prepai'ing the trnstees, repoit and fyoin the requiiEment to pitpare a strategic report. Responsibiliti¢8 of tru8tee8 for the finanelal statements As explau)ed more fully in the trustees, Itsponsibililies statement set out on page 12, the trustees {who al'e also the directors of the chai'ilable Company for the purposes of company law) are i'esponsible for the pi'eparalion of the fiiioncial st3temeRts and for being satisfied that they give a true and fair view, and foi. such ii)ternal co￿trOl as the ts'ustee5 deteiinine is necessary to enabl¢ the piep&ration of fuLan¢ial statements tliat are free from material misstatement, whethei. due to fi'aud or erJDr. In prepai'ingthe fJnancÈal st&temertt$, the trnstees ai"eresputibible for assessinbN the cliAritable company's ability to continue as a goi]ig concern. disclosipg, a$ appliLable, matters i'yldled to going conL￿'ll and usii)g the going cottceLtt basi$ of accounting iinless the trustees either ijilend to Itquidate the charitable coittpany oi. to cease opeixtions, or have no I'ealistie Iternative but to do so. Auditor's respopsibilities for the audit of the filluDcixI SlatE￿ents Our objectives al'e to obtaill reasonable a55uI'allce abuut whethtrr ihe fjnaiicial statements as a whole are free fi.om m2terial misstatemellt, whether due to frttud (Ir eiyui., and to isbue duditur'b repvrt that lliclude5 OUI. OPTfiioEi. Reasonable assurance is a hig] level of assurance, but is Dut d gu￿&￿1￿¢ thilt dn audit LoinduLtEd in 8LCUI"dunLe with ISAS (UK) will always detect a material mi55taternenl whtrn it exists. Misslatemenls ban ￿'1￿C from frdud vr ¥m)r and iire considered Inaterial if, individually oi. in ihe aggreg£lt¢. they ¢ould reasonably be expected to infiuence the economic decisivlls of useiE taken 011 the basis of th&se f￿anCIal statements. Ir￿gUlaritIes, iDcliiding Ci'aud, are in5tallLfS of non-coinplianLe with IAWS Kind r¢8ul¢iÉiiJIi&. W¢ d¢bigD pIDLrdiires in Itne with ouriEsponsibililieb, Outlined 41buve, lo detect matei'ial ii)isstatements respect of irregulai'itias, inLlvding fraud. The extent to which our pruLedur¢5 arc LÉtP(Ible of detecting in'egulai'ities, in¢ludin8 fraud is detailed below.. Based on our undeistanding of the charitable company and the envirornment in which it operates. we identified that the pyincipal risks of non-cotnplidiiLe wilh Idws and iegulatioiis Irlaled io the Coinpanies Acl 2006 and Charities ALt 2011, and we considered the Extent tu whiLh non-compliance might have a malerial effecl on the fmancial bla(ements. We a150 coiisida'ed ihuse Idw5 (Ind r¥gulations that have a dii'ect itnpacl on the pjeporntion of the fiiiancial stateinents such as payroll tax sale5 tax. We evaluated managemeat's incentives and OppOr￿nItIeS foi. fraudulent manipulation of the f￿ancial statejnents (including the risk of override of controls), and detemiined that tlie pi'incipal risks wei'e related to postiiig inappi'upriate journal entries to i'evei)ue managementbias in accoun¢in8 es¢iniates. Audit procedui'es perfomi¢d by ihe eDgagettLEnt teain iucludEd: Inspecting conEspondence with regulators and tax authorities. Di5CUSSlOllS With Inanageiiient includii)g Co￿5￿deration of known or suspected instances olnon-cornplian¢e with laws and iegulatioll and fiHud., Evaluating inanageinent's controls de6igThed to prEvent detect iiTegularities- Review of miiiutes of meetings EdentÈfying and testing journals, in particulai. journal entries posted as part of the yeai. end process. and Cliallenging assumptions aiid judgemenis made by management in their critical accouiiting estimates Because of the inherent limitations of an audit, there is a risk that we will not detect all ll'regularities. includillg those leading to a material misstatelnent in the f￿ancIal stgttements or non-compliance with r6gul8tion. This risk increases the n)ore that Compliance witl) a law or itgulation is I'emoved fi￿M the events and tt'artsaGtions r6flected in the flliancial stateinents, as we will be less likely to become awaie of instances of non-compliance. The risk is also gi'eater regarding iii'egulai'ities occiin'ing due to frattd rather th￿1 errol., as fi?ud it)volves intentional coi)¢ealment, forgery, collusion, oinissioii or misrepresentation. 16 Registered company number.. 02645706

The British Sotiety for HAem*toloEy (Limi¢ed by guai'antccl Endépendeijt Huditor's iYi)ort Yoar En(led 30 SeptetnbÈr 2022 A ￿rth￿. description of oyi. i'esponsibilities for the 8udil of the financial stateinenls is located on the Financial Repoiting Coullcil's website at: www.fr .01 klaudi orsres ibililies. This desciiption for1￿8 part of our auditoi s iepoit. Use of our repoi't Tiiis report is niade solely to the charitable company's meniber4 a5 a body, in accordance with Chapter 3 of Part 16 of the Companie5 Act 2006. Oui'audEtwork has been utjdatsken so tliat we might slate to the chai'itable company's membei'g those inatters we are required to slate to thetn in atk Auditoi s repoi'l and for no otlier purpose. To the hllest exteiit Pet￿Itted by law, we do nol accept oi. assuiiieresp0Th5ibility to atLyoiieothei'than tlie chai'ilable company arld the charit&ble company's EneinbEr8, as a body, foi. our audit work, for this report, or foi. 11)e opinions we have fomied. Thomas Wilson (Set]ior Statutory Auditoi.) Foi. and on behalf of Haysmacintyre LLP, Statlltoiy Auditoi. 10 Queen Street Place London EC4R IAG [datel 26104123 Registered comp&Thy numb¢J': 02645706

Tht British Sotiety for HntmAtology ILinJiteiq by guArttteel Cthnsolidxted statement of finAncll aetlvitles Year endEd 30 Sepleniber 2022 GeDcrx Funds Designated Funds Tot%1 2022 TotAI 2021 Iyoles INCOMI fiROM: D0t￿tiOnS Charitable ￿tl￿tles. Siibscp'ipiioiis Pi'ofFI Shal'e ofJoiii'nals Oihei. iKcoine /n¢oiiTéfJ'oiii ihe CoiJfei'eKcé Itjvestmellt incoIne 705 705 17 233,868 1,144,431 307 1,175,034 52,465 233,868 1,144,43 307 1,175,034 52,465 215,165 1398,034 1,089515 56,668 Total Income 2606810 2606810 2 759 399 IXPENDITiJR£ ON: Roi5ing fwids Jnvesliipenl Iiya17ageiFienifees 35,855 35,855 34,256 Ch￿Itable a¢tivities'. Reseapeh Ediicalion aJ7daivoJ Cosl ofconfeienccs 618 135,343 1.117.586 1,014224 161,677 16.489 297,020 .134.075 1,0 14224 370,473 992.693 513,919 lot#] oxpendlture 178 L66 2481 174 1911 341 Net in¢om¢ before ittNtstment g8tDS and transfers 303,802 {178,1661 125,636 848,058 Net Ilosses)I gaills on in*stment8 Net income and net mowment in fu￿8 758551 1454.749) 758 551 (632,9151 620 772 1,468,830 (178.l66) TratJsf¢r between funds 94,830 (94,830) Fynd b￿anCeS blf 10,951,356 422.881 1,374,237 9,905,407 Fund balances elf 10 591437 149 885 10741 322 74 37 All recognised gains and losses are reflected througlL the Statement of Financial Activities. All activities Irflected above air continuing activities. The accompanying note5 OA] PaEes 22 to 39 forn] part of the accounts. 18 Registered company nurnbcr.. 02645706

The Bi'it15h Society foi. HaeinAtology (Limlttd by ¥uai'anlee} Consthlidated BRlance Slbeet At 30 SÈptember 2022 CompAny Niimb¢r= Q2645706 2Q22 2021 Note FIXED ASSETS Tgwble assets IthEsiments 14 421,263 7,848,147 441,410 8.579,192 8,269,410 9,020.602 CiWIENT ASSEIS Debtois C￿h at bank atyj IlLh￿)d 6t7,464 2.324 781 2.942,245 485,601 2 467,250 2.952.851 CRlIDIWRS= Ansouiits fallit¥du¢ 14rythin Dne )ear 17 (470,3331 (5992161 NETCURREwfASSE15 2,471,912 2,353,635 TOTALASSttB LLSS CtWiENTLL4BILIIIES 10,741.322 11,374.237 NET ASSEtS 10741322 113742J7 t1]￿]RICTED fuNDS: General funds DesiBT]gted fwd 10,591,437 149.885 10741322 10.951,356 422 881 11374237 The financial statements were approved and avth0ri5ed for issue by the board of Trll5tees on . and were signed on ilb behdif by Dr Josh Wright TrustLC #nd Pre5ideDt Dr A Johii Aslieroft Trustcc and Treasllrer The accompanysllg notes on pages 22 to 39 fomi pait of the accounts. 19 Registered company llumbe¥.' 02645706

The BritislL Society foi. HxEltJtology (Limited by rantec} Clixvit#ble Compny IIAIAn¢e Slieet At 30 SeptenJbeJ' 2022 Company Nuniber 02645706 2022 2021 Note FIXED ASSEIS Tawble as%eis nKrstm¢ttts 14 15 421,263 7,848,149 441,410 8,579,194 8,269,412 9.020,604 CURRENT ASSE15 Debtors Cash at bankand in hattd 16 425,959 2 197336 2,623,295 327,727 2018420 2 J46,147 CREDfiDRS.. Amoullts fallingdu¢ ithin one ye￿. 17 {463,924) 590 762 NETCURRENT ASSE15 2 159371 85 TOTALASSETS LESS CURRENT LIABILITIES JO,428,783 10,775,989 NET ASSETS 10428783 E0775989 UNRESIRICIED FUNDS.. Qencial funds De8jgnaled funds 18 18 10,278,898 149 885 10 428783 10,353,108 422881 10 775989 The financial statements were approved and audiorised foi. issue by the board of Trustees and wei'e signed on its behalf by Dr Josh Wright Trustee and PresidEnt Dr A John Ashcroft Trustee and Treasuyer The accompanying notes folm) part of thr accounts. As pennitted by Section 408 of the Companies Act 2006, no Separate Statsment of Financial Activities or Income and ExpenditUlE account ha5 beEn presented for the charity alone. Income of the pairnt charity alone amounted to £1,794,236 (2021.. £1,669,881). Net expenditure of the charity after realisedlunrealised gains oil invest]nents amounted to £434,935 (2021.. £893.234}. 20 RegiS￿￿d company numb¢i-. 02645706

The British Soci¢ty for FIaeEnatoloey {Li41Jlted by gUAr￿￿tet) cons01idRted C%&li FIDIY Stxtemcllt Year ended 30 September 2022 2022 2121 CA8h lioyys fvom OPÈi'Atifjg xctiilltie5-. Nti ¢￿h9[olryQ￿a byllw¢d inl orKr4tiiigtiiryti¢s 1167,4291 471235 Cw$h Iloivs fi.D￿l lJkVESting activities DiYidtn¢ts ￿ ini¢t¢st Pw¢h&s¢ of imrslmelts Pro¢e¢ds froills￿¢ of in%¥sim¢nt$ Illic￿05cl In iRlf51mcnl C￿[7 Pa)w¢nts to acq￿rg I4￿1b1¢ fi￿d&sse1s Nti e&li prowthdby li1vesti￿ liMlieS 52.465 12,378,650) 2,471.189 1120.0451 56,668 17,369,087) 6.438.345 15,7521 882 036 ChATh¥c essh siid cRsh cqDivalollts In the repDrllKg pei'iod 1142.4701 1410.8011 Cash eRsh eqTIlYAleDls at tht be¥inning ofthe r¢¥orting pei'lod 49 2 878 050 Ca5b ADdeAsh EquivRlents fit Ibe end oflht r¢pLbrli￿￿ pcriod 2 324 779 2 467 249 NOIES TO IHEsfAIEMENTof C4SH FLOWS IA) Reconciliatlolk ofNtt Moytmc￿t In Ilund$ to Nct Ca511 fioiy fi'otn Operallng AetlFrytie$.' infunds.. Nel gainon lil￿sInients Depre¢i&tion DeCr￿e/ll￿e&e} in deEÉors Jtwease in creditors DividBiids, interests ￿d￿ents frotti li￿est￿￿) 1632,9151 738,551 20,147 1131,8631 1128,8841 152.4651 1,468,830 1620,7721 20.328 169,009 1509,4921 156,6681 Nett•sh pi'ovlded byllvstd Inl opeyitlng fyetliryties 167 429 471 35 (Jll An￿1￿15 0(Cgsh A]kd Cash Èqlllv81eht$ 2 467 249 The a¢¢ompanying notes forni ail integral pait of these accounts. Thei'e were iio debt a￿angementS entered during the year. 21 k¢8isi¢Ted Gompyny numb¢i.' 02fv15706

Tlie Britisl) Soeiety for HAematology (Limited by guarantee) Notes to the fJnaneiAI stAttmentS YeAr endod 30 September 2022 COMPANY STATUS The company is limited by guai'antee, not having a Share capital. The members ￿nd￿tske tck contribute to the assets of the company in the evelll of it being wound up, either whilst Imernbers oi. within one year of the embership ¢easinB. The maxIm￿ill contrib￿tIon required from each metnber is £1. There were 2,947 active illEmber& at 30 September 2022 (2021.. 2,847). ACCOULYfiNG POLICIEI S Statement of eomplianee The f￿ancial stateineiits have been prepared im accordance with A¢counting and Reporting by ChAtities-. Statement of Re¢oininended Practice applicable to chai'ities preparing iheii. aC￿ll￿ts in accordance with the Financial Reporting Standatyi applicable in tlie UK and Republic of Ireland (FRS 102)- (Charities SORP 2015 (Second Edition. effective l January 20191, the financial Repoiting Standard applicable in the UK at)d Republic of tteland {FRS 102) aiid the Conipanies Act 2006. Assets and liabilities air initially i'ecognised at histoi'ical cost or tra*saction value unlesg otheiyise slated in the relevant accounting policy notes. G¢nei'01 iiiformatlon The Charity 1$ a Col￿partY limited by guaiyntee, in¢orpoiated in Englaiid and Wales (company number.. 02645706) and a eharfftty re¥ibiered in Englai)d and Wales (chai'ity numbei.: 1005735)- The Charity's i'egtstered office ad(h.ess is 100 White Lion Street, London N19PF. The British Society foi. Ha¢m&lology meets the defmition of a public benefit entity under FRS 102. Consolidation The a¢c(WDls conSol￿date the fmancial statements of The Biitisli Society for Haematology akd its wholly-owiied subsidiary, BSH Ei)terprise5 Ltd, on a line-by-line basis. Tiansactions ai)d balances between the charity and its subsidiary haye been eliminated from the corjsolidated fJn8ncial statement5. As pei'mitted by Section 408 of the Compallies Act 2006, no Separate Ststeinentof Financial Activities or Income and Expenditure account ha5 be¢n pro5ei)led for the charity alone. Income of the parent Chai'ity aloTre aniounted to £1,794,236 (2021.. £1,669,881}. Net expenditure of the charity after realisedlullrealised gains OTE investtnents amounted to £434,935 (2021.. £893,234). Going coThc¢r The Tivstees have reviewed the Resei'ves Policy alld the forecasts for the next two yeai's and consider that there aiE no malei.ial unceitainties about The Brstish Society foi. Haematology's ability to contlliue in existence and it h8$ adequate i'esources for the neai. futhiE. Cunent levels of investtnents and cash fi]iids are in exoes5 of the Reserves Policy and tlie Charity has the ability lo curtail expenditure lo a Jnii)im81 level of overheads. Evely quartei. the FARC reviews Inanageinent accounts, budgets, and 24 month cash projections. The budgets prepared for the coming financial year will carefully consfftder the control of outgoing expenditure to be in lÉne with the ¢UlTent income streains, Any effect on levels of income due to the pandemic, and any incr¢ases in ijicoine resulting from the projects to diversify and illcrease income. R¢gisl¢red £omp8ny nUt￿ber.. 02645706

The British Stsci¢ty for HaemAtology (Limlttd by guarAthtÈel Note8 to tlie finRiicial statements (conriiiii¢dJ Year ended 30 S¢pternber 2022 ACCOUNTING POLZCl&S (eontinued) Ct'itical aocounting judgetneRts a￿d estimates and key sourees of estimation uNcertAlnty lji the application of the8e accouiitll)g policies. Ihe Th]stees are 1'equ￿red to make judgeinents. estitnates and assumptions about the ¢arryÉng value of assets and liabilities that are not i'eadily apparent from other sources. Estimates and judg¢inenls are continually evaluated and are based on historical expei'ience and othei. factors, in¢luding expectations of ftiture events that al'e believed to be reasonable uiidei. the circumstances. Although Ihese estimates are based on InallageTnent's best knowledge of tlie amount, events oi. actions. a¢tual results imay ultin)ately differ fi'on] tbose e51iinates. Revisions to accounting estimat65 al'e recogiiised in the period in which the estiinate is i'evised if the revision affects ollly that peti<￿ or in the pei'iod of the i'evision aod futtEi'e p¢riods if the revision affects curretkl and future periods. The Tlugtees consider the following items to be areas subject to estimation and judgern¢nl'. Depreciation.. The use￿1 ecoaornic lives of tangible fixed assets are based on Inanageiyienl's judgcment and experience. Wliell m&nageinent identifies that a¢￿al useful economic lives differ malyrially fi.om the estimates Iised to Galculate depreciation, that chai'ge is adjusted retrospeotÈvely. Although tanxible fixed assets are significant, variances b¢lween aclual and estllnated useful econoinic lives will not have a rnalerial in]pact on tlie operatiTrg results. Flistorically, no changes have been required. In the view of thE Trnsteu, T)0 assumptions concerning the future or estimation uncertall)ty affecting &58ets oi. liabilities at the balance sheet date are likely to result in a material adjusbnent to thell. cariying ainount3 in the next financial yeai.. The followitlg accounting policies have been applied consisteiitly in dealing with items which al'e considered material in relation to th¢ finan¢ial statements. Income All iE]corne is recognis¢d whell the criteria of entitlement, measurernent and probability of receipt have Ixen satisfLed. Membe1511ip subsci'iption income is accounted for on an accrual basis and represents only that part of the sub5CEiPtion which relalo5 lo the f]nancial year til wl)ich it is paid. The balai)ce is included in defeiT¢d Encome in CLtditois oll the balan¢¢ sheet and released in the peiiod to which it relates. Dividend iiicoine is accounted for in the statement of fin&ncial activities in the period fft which th¢ chai'ity is Entitled to receipt, The profit share i'eceiYabl¢ from John Wiley & Sons Ltd in respect of BJHoem and eJHuem is i'ecognised on a receivable basis. Turnover in BSH Enterprises Limited i'epresents the atnounts (exeluding value added tax) derived fi'om the provision of the annual conference foi. The Bi'itish Society for Haematology. TumovEI' is accounted for on an accrual basis with income recognised in the pi'ofit and loss account foj. Ihe ¢onferenre completed iii the Gu￿ent accDUtatiiig period. Deposits i'eceived in respect of the confrrence in the next aCcou￿tIng period are held in defeETed income in cirditors ll) the balance sheet at the year end. 23 Rcgistcrcd cornpany number.. 02645706

Tli¢ British Soci¢ty for H&e￿lat01￿ ILirtittd by g￿￿tAntee) Notes to the fiJJanciAI statÈmÈnts (coiiliiiiied) YEar ended 30 Sopte]nber 2022 AccouNfING POLJClfi S (contiiiued) Expenditure Liabilities are recognised as resources expended as soott as there is a legal or constwctive obligation commilling the Gharity to the expeiiditure. Expendi￿re is accounted for on an accruals basis and has been classified unde¥ headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings. they have been allocated to activities on a basis consistent with the llse of resources. ExpenditUlE is classified under the following activity headings., Costs of raising ￿ndS comprise the costs of lnvestsnent management and other support ¢051s that do nol IElate diirctly to sepai'ate cliaritttble activities. Expendituir on chai'itablc activities ll)cludes th¢ costs of projecls on health and education and their associated ¢osts underlakeii to thithei. t]ie putyoses of the charity. Support costs Iiave been allocated to direct activities based on the total direct costs of each function. En'ecoverable VAT is Charged as a cost against th¢ activity for which the expenditure was iucurred. Gi'aiit aw9rds BSII invites applications for funding of research start-up grants for young investigatois in haematology. BSFI also awai'dq 9￿dent schol&rships k)nd scholarships to assist haematology professionals to visit overs¢as InSt￿bIli0nq for the purpose of leaming new research or clinical techniques, In addÉtion, BSH awai'ds trave s¢holaiEhip8 to et)ablc liaeInatology nurses. physician associates, students, doctois oi. seientEst8 in tt'ait]ing to atteild overseas meetings. Applicatioiis are made tt> the Scielltific and Publications Committee (i'enamed tlTre Research and Grallts e.ommittec in ScpteInber 2021), which is assisted by independent expeit IEviewers for the higher-Yalu£ Eesearch grants. Thc Board of Trustees approves anDual grai)t budgets and iryiews expendituir i'egularly. The liability for the ￿￿nt is recogllised at the point the relevant cominittees authorise the award of the gra￿t. Oper&ting ItAse8 Rcntals payable under operating leases are charged to the statejnent of f￿anCial aotivitie5 over the terms of the lease. Short-term beiiefits Shoit tem) benefits, including hotiday pay, are recognised as an expense in the peiiod in which the service is r¢¢eiv¢d. Pen$ions Th¢ Charity contTiliutes to tbe NEST defmed conti'ibution sch6m4 contributiotss are mad¢ in accordance with the rules of the plAn and are charged ¢0 expcndiknre wh6n they ait payable. Employee terminatlon benefits Tettknination benefits are accounted foi. on an accrual basis ai)d in line with FRS 102. Fixed asset invcstmeiits Quoted investments are stated at market value at the balai)¢e sheet date. The investment in the subsidiaiy company is included tn ihe &ccounts llt Cost. Flxed assets aiid depreeiation Items are capitalised if cost IS g￿ter than £1,000, otherwise they are written off directly to the Statement of Financial Activities. 24 Registered eompally niimber.. 02645706

The Britisli Society for HAeRiatology ILiMlted by giiAfRlJteel Notes to the finaiiciRI stfitemtnts (covliKii¢d) Year ended 30 Stpttniber 2021 ACCOUNTtNG POLICIC4 S (continued) Depi'¢¢iAtÉon these assets is provided to write off the cost of tangible fixed assets by equal i118tahnents ovei. theii. estimated use￿] economi¢ lives as follows.. Long leasehold property Offtce equipment over 50 years - 20D/o per annum Taxation The Society was registered as a charity in Novembei. 1991. Und￿. s505 JCTA 1988 the charity is not subject to taxation oll its cliai'itable activities. The profits of the non-chai'itable subsidiaiy are gifi aided to the paY¢nt coillpaTry at the DllECtors' diseiEtion. Any surplus iEmainiTig is subjecl to a taxation charge. The cliai'ge foi. taxation 15 based on the iwult foi. the year. Fund accouDtillg Th6 Society has the following types of fvnds ftsi. which it is Irsponsible alld which i'equii'e separate disclosures. Geiiei'#l funds Gei)eral fvnds aiE unresb'icted funds. and th6se are expendable at the discretion of the TnESte¢s fulthei'd￿¢e of tlic objcctives of ihe company. li) addition to expenditure on the pi'incipal objectives of tlie ¢oinpany, buch funds may b¢ Iicld in ord¢i' to finance capital i￿veStment and working capital. Designated funds Dcsignated funds Comprise u￿eStriCted ￿ndS that liave been set aside by the Trustees for particulai. putposcs. Restricted funds Restricted fuEJds are funds subjected to specific irA8tNctions by the dollor, but still within the objects of the charÈty. The Society CUlTently has no Restricted Funds, Tran5fei's between reserves T17nsfers between gen￿'al and designated ￿ndS are made at the Tiustees, discretion to set aside fullds as requir¢d. Financial Instruments The Chai'ity only holds fit)ancial assets and fthancial liabilities of akii)d that qualify as basic financial insb'utnents. Basic r￿In¢la] inskn'uments tijolude trade debtors, accrued income, other dcbtors and loan amoiints due from subsidiary undertakings. Basie fmancial liabilities include tt'ade creditors, acerua15, and i)ther ciEditor5. BasÉc f]nancial insttuments al'e initially recognised at trans&¢lion value aiid subsequently measui'ed at their settlenient value. Debtors Trade and other debtors are recognised at the settlement due after any tr8de dis¢01]nt offered. Prepaymei)Is are valued at the amount prepaid net of any trade dEscourils due. Creditor5 and provislorts Creditors and provisions are ircognised where the Chai'ity has a presertt obligation resulting froin a past event that will pi'obably result in the transfer fuiids to a third party and the ainollnt du¢ to settle the obligation can be easwed oi. estimated reliably. Creditor& and pl'ovisio￿S are normally recogmised at their settleinent amount aftej. allowing for any trade discouiits due. 25 li¢gislered CQTnpany number.. 02645706

Tlic Bvitlsh Society lor Haematology (Limittd by guarantc¢l Note8 to tlie fLn%ncifil st%temcJits (¢oiiliiiii¢¢l) Year ended 30 September 2022 DONAT]ONS 2022 2021 Cenerol fund5 DoTkations 705 17 Total donations 705 17 OTHER INCOME 2022 2021 G¢neral fuiid5 Sundry income 307 307 INVBSTMENT INCOME 2022 2021 G¢neral fund8 Dividend and retums fi.om investments Other interest i'eceivable 47,388 5,077 56,425 243 52,465 56,668 26 Regisl¢LEd Company number.. 02645706

Tlje British SDciEty for Hacmatology (Limited by guai'anteBI Not¢5 to the financlAI stat¢m¢￿tS (coiilijiiied) Ye￿r ended 30 Sept¢mLTrer 2022 RE4SEARCH 2022 2021 Research is a¢liie¥edI￿OUBh the twtnent ofih¢ folloHing wgnts.. E￿lY Slag¢ Res¢srch 81% up yattt St￿￿ent¢[eCti}Es BSH ASM S¢holtLhips' intludiDg for studcY¢s S¢i¢niifi¢ Meeiingsiipwrt V&siljDg Fellow Global HaBm8tologygTgnls (from Des1￿¥￿e￿ funds) Coliort Study grgnt (from Desip>aied hu￿8) 18raTrt. 2021 1 I ￿a￿¢S IS ￿llts. 20214 ￿ants 19 wants. 20212 ￿&￿ts 4 gr8nls O graols., 2021 1 2 ￿a￿lS,. 2021 1 gxnt I ￿an1. 202L I ￿8￿l 1,969 4.157 6.378 3,040 162,323 3,243 225 11,0001 17.997 1,809 48,455 14,263 49,812 79,619 233.052 Supw)Tl¢osts Is¢¢ note 81 Ellood Cancer UK (from Dttsignated Futd51 119,799 97.602 107,421 30,000 297 D20 370 473 Alotsi of4212021.. 201 gronts Mere aw8r(kd inthe 3ear. tn¢lu&d in the aboNE are th¢ follo7¥ingw￿lS paid 10 itislitulions. All olhei, gr￿t5 &WJfded diiEctly to Iiidi￿dua[s. 2022: uni￿rSitY0f Oxford £49,812., Unl￿¥$liy0f Ca￿bi1d8e £4,628 21J21.. unl￿￿.%1tyOf Oxford £48.455 Jn th¢ preiious Y¢￿ th¢ BSHb¢¢ie imemkr of the Covid Vgccination FundingCollabDrat]￿ l¢dby Blood C¥mcerUK. The oject ¢wThes ouiJEseareh iLlo effic&oy of coirydvacciii¢ forpeopl¢ Thilh bluod cancer. A tal￿ of £150,000 was desi￿ted foi. thc BSH ID a%sist this cDIlaknr3ti￿ ()f ￿￿leh £97,6n2 Jw been paid to Blood Canc¢r UK in 2022 {2021.. £30.0001. 27 Registered company nllmbcr.. 02645706

Tlie British Society for Hatmatology (Limited by g￿arantee) Note5 t4J tlie fith8nci#l statements (coiiliniieLI) Year endid 30 Septctnbcr 2022 EDUCATION AND AWARENESS Gutdelines Cosl5'. Commiltee general 6xtKn5e5 Haeinatolo&vlthromiKisis i&%k foire IIacmatolo£YlOiicDlogy task foT¢¢ Getteral Haematolo&v Igsk foi'ce Tr8Th8fl￿a0ll la5kfoire Literature searches & Medical Mriting Retitrd consultaTJts & Irainees Digital Media cost5 Educat&onal cotnn]ittee Lcai'nillg Manageillent SystBIll C051s Meinbei'ship develo￿]ent Paediati'ic SIG t￿llts Obsteti'ic SIG t￿nL Lab SIG c￿ntS Lymphoma SIG eTrEnt5 Pi'og'amme Cornmitte¢ ex￿nSeS Genomics Working Group Othei. C4)mmilte¢ ex￿￿3¢5 Educational ser￿c¢s & Jownals Annual Science Meeting Cxk5t5 Prizes & Excellenc¢ Awards Webb'ite O)sts Educatioiial Events C05t51{In¢ome} Contribution to extejnal e*nts Wilkin50n l.ectUTe ca%t (from Desi￿ated Punds) Woi'lfjorc¢ Suiwb'y & Campaigning 2020 ADniveTsury Commemoration Costs (from D¢51￿￿ted l.'unds) 50 125 200 4J,960 15,721 400 9,098 340 3.790 12.019 10,000 (205) 40 2,706 280 255 144,918 375 3,250 237.552 1203 6,500 120 137.993 2.437 3,250 37,123 761 33,147 16 69 471,183 117 570 398,295 Supwi't costs (5¢¢ nol¢ 81 662,892 594,398 1 134 075 992 693 28 ReElStered company number.. 02645706

Tlit BYit1511 Society for FtAemAtology {Limited by BuarAiiteel Notes to tlje fin8ncig1 statements (coitiiiiiiÉd) Year eiid¢d 30 S¢i)tetMber 2022 XPENDTfuRE Dij'ect costs GrRnts pAyable Suppoi't C05t5 Total 2022 Cost of rwsing furyjs Invesimenk mdnogeJl￿￿IfgeS 19.882 15,973 35,855 (hitable activittC8 RgsgoFclp Ediicolion dndoiirarertets Co&1 ofConf8J'ences 97,602 471,183 1,014,224 79,619 119.799 662,892 297,020 1.134,075 1,014,224 1602.891 798 664 2481 174 EXPEIYDIIiIRE PRIOR yLiilR Direct costs Graiit5 payAblt Sypport cost$ TotAI 2021 CD5t of raisiT]g fur¥Js 1nvesimenlJ￿O￿d9éMett1Jee 19.933 14,323 34.256 Chw'itablc actiiryltcs Research 30,000 398,295 513,919 233,Q52 107,421 594.398 370,473 992,693 513,919 Cosf of Confeiences 962 147 233 052 716 142 The b1818 of allocation of supwvl Costs is based on an allocation of estimattd staff lime. Support tost&- othty 2022 2021 Salaries & other staff costs PT¢in15¢5 Costs otYi¢e and computing Profess%0￿ fee5 Mwkctitkg S92,132 59.262 6Q,760 46.888 1,358 549,550 55,696 55,032 22,967 389 761,941 684,919 SuppDrt costs- goverllartte Audit cosls tÈgal costs Trwl¢¢$' & Goiri'nanoe tllcelitE5 12.255 3,504 11,350 7.893 36,724 31,223 798 665 716 142 29 Registe¥ed compaTry number.. 02645706

Tli¢ British Society for Hatmltology {Limited by guArAllteel NotÈs to thé finathtlAI stlltemtnts (tollllijiied) Ycar eiidcd 30 September 2022 INVEI STMENT AND OPERATIONS IN TRADING SUBSIDIARY The wholly owlled trading subsidiary, BSH Ente￿.]$¢$ Limited (02677826), which is incorporated in the United Icingdom and registered iii Eiiglalld and Wales, pays its pi'ofit by gift aid at the di5¢retion of the Directors. BSH Enterprises Limited operates th6 Annual Scientific Meetii)g (ASM) and 011 commercial trading operations. The charity owns the entii'e issued sliare Gapiial of 2 ordinary shal'es of £1 each. A suminaiy of the tr8ding i'esults is shown below= 2022 2021 Tw'novei. Cost of sales Cross (los$)/profit Adininisli'aliK exp6n5eS Operating (Ios5)Ipi'ofit Fi[W￿6 C051s Intcrest Irceithle Profiil(loss) on ordinary activities befoi'e taxation Taxation Gift Aid paid 1,175,034 1004 857 170,177 13,872 156,305 (1,136) 1,089,515 498 998 59U,517 576,689 11,096) 155,175 575,596 {440,884) 285 709 575 596 The 835ets and15abilities of the subsidiarymtre.. Current assets due wtthin one ye Debtoi's due after more than one yew. Creditors.. amounts falling within OnB year 308,183 I C),407 12,049 312,541 556,261 86,866 44,877 598,250 Share capital and reser￿5 312,541 598 250 30 Regisl￿Ed company number.. 02(A5706

Th¢ British Soeiety for HAenifitolo8y (Limited by guArAntte) Notes to tlit financixl st%tenients (CQJfliniiEd) Yeh Y ended 30 Septejnber 2022 IQ. NET INCOME 2022 2021 Net income 15 Stated after chai'ging.. Auditors, i'Bmuneiztion- Audit of these fthaTrcial stateinents (exGluding VAT) Audit the subsidiary fmancial st&tements (excluding VAT) Other services Depi'eciation 9,680 5,350 2,100 20,147 9,050 5,000 1,950 20,328 REMUNERATION OF TRUSTII ES The Trustees ￿e1ved no Temunei'glion during Éhe year, or the pr¢vious period. 9 Trllstees received reimbursernent of expenses lll the yeaT of £2,257 (2021.. 4 Trustees. £519) These expenses related to h'avel and subsist¢llce necessaTily incunEd in the perfomiai)ce of their duties. No amounts were paid directly to third parti¢s. 12. STAFF NUMBERS AND COSTS The average number of persons, einployed by the group dui'ing the yeaj. (excluding Trustees and Directoi's) was 11 (2021.. 1 l). The average numbei. of persons in¢ludll)g teinpot7ry staff was 14. The group aggregate payroll costs of these p¢r30ns were as follows: 2022 2021 Wages and salaries Social Se￿rity costs Employers pensioll Tempornry staff 405,179 40,085 33,345 93,232 379,fv48 35,332 31,089 76,925 571,841 522,994 There wa5 1 employee wh05e emoluments for the year were between £60,000- £70,000 {2021- 1). The key management personnel of the gi'oup illclud¢s the Tii¥stees aiid Directors of the Senioi. Management Team. No trustees wei'e remunerated during the year (2021.. nill. Total I'emuneration to the key manÉtgement peisonllel was £74,144 (2021.. £73,837). 13. TAXATION The company> which 15 a registered ehai'ity, is not liable to tsxation on the net income fiDm its charitable activities. Registered company nuimber., 02645706

Tht Britl51i Socioty for Haematology ILimlted by gllarRtiteel N(btÈs to tlie fJnan¢iAI statements (coJ?liiiiiEd) Yeai. ended 30 Septeiitbei. 2022 14. TANGtBLE FtXED A&SKTS Property & irnprovements Office Equipinoiit Total 2022 Group alld ClJarlt#ble Company Cost At l October 2021 Additions Diswsais At 30 September 2022 604,759 49,640 654,399 604 759 654 399 Depreciation At I October 2021 Ch&'ge for the year De￿.¢¢Iation on disposals At 30 Septeinber 2022 178293 13,840 34,696 6,307 212.989 20,147 192 133 233 136 Net Book Value Ai 30 september 2022 412626 421263 At 30 SeptemFKi' 2021 426 466 441,410 32 R¢gi5tsTrd eompany numb¢r'. 02645706

The British Society for HAemAtology {Limite(I by guArrtnteel Notes to tbe fIn￿￿tI￿[ stAtement8 (c07tliffiiedJ YeAr tnded 30 September 2022 15. FIXED ASSlITll¥VESTMENTS 2022 2021 Group Investments at l October 2021 Additions Disposals Redised gainl(losses) Um'ealised gains TotaI In￿strnents (exC1L￿lng cash) Cash held in In￿StMent poi'tfolio at 30 September 2022 Unlisted iiivestments At l Octobei. 2021 8,547,E06 2,378,650 (2,471,189) (209,917) (548,634) 7,696,016 152,030 7,848,046 6,995,592 7,369,087 (6,438,345) 584,965 35,807 8,547,106 31,985 8,579,091 101 Additioi at 30 September 2022 101 101 Total Investments at the end ortlje year 7,848,147 8,579,192 Histoi'ical oosts of listed investm¢nts are £3,418,883 (2021.. £3,728,431) Charitable compaiiy Listed Investnieiits At l October 2021 Additions Dispisals Realised gains/(10s8¢5) Unrealised gaiTrs Total In￿StMents (excludÉng casb) Cash held in lil￿stMent portfolio At 30 September 2022 8,547,106 2,378,650 (2,471,189) (209,917) 548,634 7,696,016 152030 7 848 046 6,995,592 7,369,087 (6,438,345) 584,965 8,547,106 8 579 091 Unlisted investments at l October 2021 Additiolls At 30 SepteTnbeT 2022 103 103 103 103 Total iiiveslments at e￿d of year 7 848,149 8,579 194 The charitable Coinpaiiy owns the eiilii'e shaiE capEtAI (two £1 ordina]y shares) of BSH Eiitei'pri5¢5 Liniited. a company registered in England and Wales. The company organises Conferences on behalf of the Brit15h So¢iety for 14aeinatology. The i'esults of the company are consolidated in tliese fukancial statements. The chaiilable conipany a150 Dwll5 10/0 of tli¢ sharB Gapktal (101 £1 ordinary 5har¢s) of The Angel Office Village Ltd, a conipany re815tei.ed England and Wales. 33 Regist¢red company nutnkr.. 02645706

The Britisli Society for H￿t￿ltO10gY ILiipi¢ed by guai'anteel Not&8 to the fillAncIAI 5tatenieiJts (coJiliiTiied) YeRr ellded 30 Septttsjber 2022 16. ChAritAble eompnny 1022 Group 2022 2021 2021 Dut iii Itss tI￿noi￿ yeer Trad¢ debtors Prepaymertis attd Atcrued income Ollier taxes 2nd social stcwity Amounts du¢ from subsidiaryu￿rtaknllg 3,360 395,375 420.319 327.727 528.059 72.998 5,640 425.959 327,727 601.057 398,735 in more ott year.. Prepayments and awrued iJLcome 16,407 86.866 Total (kbtoj's 425,959 327.727 617.464 485,601 17. CREDrroRS'. ajktsllnts falllnE d￿t Chiviabl¢ cotnpaT]y Gi'oup 2022 2022 2021 2021 within one yexr Tr4ik cr¢ditor5 Oth¢T taxr5 fjnd SOCI￿ %Burity Othei. credito¥s Accruals for ￿antS payable Accruals at￿ deferred I￿Ome {8ee Eelow) Amounts 0￿d to subsidiary unthrtaking 130,577 72,594 12,717 129207 2,832 271,905 174.101 131,235 72,594 34,043 92,784 17,832 271,905 182,652 47.469 207.163 47,469 212,914 463 924 590 762 470 333 599216 Dcferred income Subscriptton income Other deferred incomc Totals Accr￿￿5 Total actruals And deferrtd Ineomt 55,581 55,533 20 56,753 117348 174 101 55.581 4.680 60.261 152 653 212 914 55.533 60,261 146902 207 163 56.753 125 899 182 652 Defen'ed subscription income occurs ag subscriptions are billed based oil the Calend￿ year. Three months. worth of the 2021 subscription incoine is defenrd to the 2021r22 fIn[￿Cial year. Other defei'red ill¢oEne relates to edu¢t1tional courses income received for the next fmancEal Period. The deferTed confely￿Ce income from 2020 (cancelled due tts the pandeinic) has been re[￿Sed into the Statement of Finallcial Activities for 2021. 34 Regislered company number., 02645706

The British Society fDI' HiemAtology (Llmiteil by guiranteel Notes to tlie financial Stat￿mE1)t¥ (c0171init¢d) YeAr ended 30 Soptemb¢r 2022 18. TOTAL FUNDS De$lgmAttd funds Gell¢i'al fuii(1s Total 2022 Gr•up At l O¢ltsbei 2021 Net illcomdleipeTLdiiwel Re￿}￿lI9n of in￿stmentS (note 151 Transfers bBlut¢tt fwn(Is 30 Sept¢mFKr2022 4218111 1178,1661 10,951,356 303,802 1758.5511 L1,374337 125.036 1758,5511 149,885 10,591.437 10,741,322 Chgrlt%hlt Compxny At l Oolokr 2021 t*1 incomdl¢.Yp¢ndilw¢l Re￿￿￿8tion0f in￿Sti￿ents {noie 151 422,881 1178,1661 10,353.108 589,511 1758,5511 94,830 10.278.898 10.775,989 411,345 1758,55LI 94,830 149.885 At 30 SeptembBr 2022 10,42$,783 Dt5ignRted Balance it J Ocl 2021 Net outgoing 'ansfoi's fi'oml I'C5trYes Itol Gener4?1 30 S¥p 2022 Group aud chgj'itiblt Efjnipa￿Y Glokni FIactnatology Fund WilkEMson Reouesi BSH6othAnniwrs￿Y Cohoii Siiidy IDais RegisiTy Pr4)ject FWMII Blood ca￿tr UK Fund G¢nomi¢s FAlu¢dion Fw RegioJ)g] [￿nIS s￿pOrt 'rotxl$ 48,342 21,795 (14,2631 34,079 21,675 116,3691 149,812) 197.602) 144.8301 101.545 120,000 50.000 51,733 22.198 150.000} 422 11¥1 17% 166 49 885 The Cylobal Hacmatnlagy Fllnd is a designated fiind set up specifically to fiud ways of belping haematology profcssiaJial8 in law and iniddle incol￿e coiints'i¢s. The Wilkin50n Bequest is a designated thnd which pays for ihe Wilkinson M¢morial Lecture at the ASM each yea].. Tlie Society set up the 60th Anniversary Fund to engage fuEther with 11$ inember8 and potenlial membei's., to cel¢bi2tc thc advances in haematolagy ovei. the past 60 yeals and to look forwai'd to what the futLwe might hold for the discipline and those working within it. The S¢ientific and Publications Coinmittee ISPC) is responsible loi. administering the following Designated 'unds that Iiave beeii set up in iecent years.. The Cohoit Study (Data Registy Pyoject) Fui)d- set up to support cohort skndEes. The money will be used as part of the Sociw's ¥es¢arcli progt7mme ovei. the next 2-3 years. Last yeJr the Boai'd designated £150k to assist tlie Covid VA¢Gination Funding Collaborative led by Blood Cancer UK. The project ¢aired out resea¥¢h ijito etTi¢&¢y of Gowid vaccitle foi. people with blood cancer. Genomics Education 5UPPQrt- The Genomics Woi'king Group is working on ideas to i'ecommend to the SPC foi. how this fund can best be spent. Regional Eveiits support- to support education across the UK. BSH tntmbers will be able to apply to the fund to support initiatives in tl)eu' part of the country. 35 Regi$leiEd compatjy numbet.. 02645706

The Britisli Sotiety fov HAelliAtology (Limitcd by gu%i'akteel Notes to the fJttAneiAI st&ttments (¢Untritllfed) Yeaj. ended 30 Septeinber 2022 18. 'roTAL F[￿S PRIOR YK4R De51gDHtcd fDnd5 General fU￿￿S REStriclEd Fullds TotHI 2D21 Group Al l (ktobEr 2D20 Nel inconie/lex￿ndl￿eI Re￿UatIOn of imE%lments (note 151 TrI￿re[S between fwid5 At 30 Sepiemkr2021 620,715 1197.8341 9.284.692 .045,892 620,772 9,905,407 848.058 620.772 422.881 10.951.356 11,374,237 ChAI'itftbl¢ coiiipThny At l Octoki 2020 Nel itt¢omelle.4pendiiirel R¢valwtionof imrstmenls lTh)le 15) Tr￿15ft￿ bell￿eTh funds At 30 September 2021 620,715 1197,8341 9,262,040 470,296 620,772 9,882,755 272,462 620,772 422881 10,353,108 10,775,989 De&l¥￿a￿d funds 8gl¥nce •t l Oct 2020 Net outguing rostrves Trsjjsfers b'otD Ctntrl fuTrd$ BalHnce at 30 Sep2021 Gi'oup #nd ehg1'lt¥ble company Globd Ha¢niwoloByFw WilkiAson BequBSt BSI.160diAntu￿rsary CohoTI tstudy (Data Registry Piojc¢tFundl Blood Cancer UK Trund Genomics Edu¢aiion PUNI KBginnal E￿￿1$ Suppoil Fth TotA15 50,151 21,795 178,769 200,000 11,8091 48,342 21.795 61,199 IO]J45 120.QQQ 50,000 (117,5701 148,4551 130,000) 1150.0001 150.090 50,000 62V715 197 834 422 1111 36 R¢gist¢red company number.. 02645706

Tlie Bi'ittsli Society foi. HenIatolo￿ (Llmited by guarantee) Notes to the firtirtei#l stnteiijtijts fcovfiiTlfed) YeAr tndtd 30 Septèn)bv 2022 19. ANALYSIS OF CROiiP NEI T A&SErs BE4lWEEN FiiNDS DesiguAted Funds Genei'AI Re5tri£ted IPunJ5 2022 Fund bAIAnte$ Al JO SeptCQLbt¥ 2022 Art rtpi'es¢nt¢d by: TwJgibl¢ fixcd &se18 In￿S(MentS Cwr¢nl ass¢ls Iltthililiesl At 30 Septemlxi 2022 421,263 7.848,L47 2 322 026 10591437 421,263 7,848,147 2471911 10741322 149 885 149885 ANALYSIS or GROUP NCT ASSET5 BEfiic4EN FLWDS_ PRIOR YEAR De5ignRted F￿n￿5 Genei'al FuJ)d$ Resti'lclod TotAI 2021 Fund balaiice5 2t 30 Septejmber 2021 AI'C I'eprcsented by.. 1alleible fi%ed a8seis Inwsim#ni8 441.410 8,579,192 1930 754 10951 356 441,410 8,579,192 2 353 635 11374237 4228¥1 422881 AI 30 SepiembeT 2021 20. OPERATING LEASE COMlWttTMEINTS As at 30 September 2022. the charity and group's future minitllum op￿ating lease payments are as follows.. 2022 Charity 2021 Chirlty Group Gi'oup Uffice V.qvipm¢nt Within one ye&. BetW￿n and fiw ye&.5 854 I,U32 854 763 763 1,886 763 763 The a￿Ou￿t5 cl)arged to the St&tement of FinanGial Activitie5 the yeai. was £1,412 (2021.. £1,412) 37 Rcgist¢r¢d rompuny number.. 02645706

The Bi'itish S(bciety for HTrematology (Limited by guarxllteel Notes to tlie fin*neial statements l¢onii17tied} Year 30 September ZOZ2 21. PENSIONS The Charity contributes to the NEST pei)sion scheme. This is a defined contt'ibutioi) scheme, contributioi)s ale ade in acctsidrtnce with tlie I'ules of the plan and are Charged to expendituir when tlley Are payable. ContrÉbutioJ8 to die scheme totalled £33,345 (2021.. £31,089), At the year end contt'ibutions totalling £4,250 (2021.. £3.913) were outstandiiig. 22. POST BALANCE SHEET EI VENTS W]ii18t the Trustees are not co￿p1acent, tliey are confident that the Society's substantial iESei'ves will see Ilie organisation thi'ough thi5 difficult time, given that the Society reinains in a stToiig p05ltion a year into the pandemic, and the following areas are being carefi]Ily %nonitored.. Risk Registers,. reviewed annually. and now includes references to a global pandemic. the company also signed off a completely I'evised Disaster Recovery Plan during the year and this will be monitoiyd and added to as appropriale. e.g. cyber security issues; Annual budgets,. quarterly results are I"eviewed against budgets and levels of expendittji'e are controlled., BJHueiii And ¢JHaein royalty income,. regular contact with the publisher and co-owTher Wiley. to monitoi. levels of tt?ding and unexpected fluctuatioiis. The Trustees contillue Éo woi'k very closely with Wiley on looking at new ways of genei'ating income from corwrate partners. i 2022 the ienegotiation of the coiitract with Wiley will begin.. The bulk of ll)einbership subscriptions aiE ¢ollect¢d iii January which Ineans thot the Trustees ai"e aware of the current year's level of Inembership u]come al the date of signing tlie accounts (April}' The bARC obtained a third paity review of the investsnent poilfolios in spring 2022 and. along with the Trustees Board, al'e disoussing their recon)Inendations. tncome diveTsifi¢ation,' Many AqM.%panqoi'% arc kecii to continue to SUPPOlt BSH including outside of the ASM, e.g. by suppoitii)g online %ef8ion.% and wehinaiB. The Directors of the subsidiary undertook are-tendei'pi'ocess Coi. the Professional Conferejiee Organiser (PCO} iii ea]'ly 2022, and a new PCO was appointed in June 2022. They have a thi'ee-yeai. contract with a biEak clause at olle Ye￿.. The Society is at the beginning of a I￿.ge workforce project. and are cun'ently tendering for a p2rtner organisation to help it look at three majoi. areas of the haeinalology workforce. 38 R¢gi5t¢red tompany Jiumber.. 02645706

Tht British Society for HAtmAtology (Limited by gurAntee) ConsDlldAtÈd sttÈmnt of fJnanelAI &etlvitlts YeaT Biided 30 Septembcr 2022 23. FRIOR IfARSTATEiTrtlTJYfoF FtNANCblLACTIVITilIS CL'iieral Funds DcsiElllitcd Total 2021 Nol¢s Intome from D￿T￿￿tio[L5 Choi'itftblÉ rteiiviiles.. Suiiscriptions ProfTt shsrc of BFlt15h Jom]ai Df H&tsJ¥olugy other income Incrjme froni IFr OPBr8tion of ctrnFe1ei￿eS In￿51￿]ent inctsrtie lolal l11c￿￿l. 17 17 215,165 1,398.034 215.165 1.398.034 1,089,515 1,089.515 2 759 399 2,759 399 ExrENDI'JUIiE ON.. R2isinE fuTrds lttNtsimettl ni¥nagcmcnt f¢es 34.256 34256 Charilabl¢ aCtI￿lieS Res¢wth EducDlion and &WareT￿$s Cost of O￿18￿￿0￿0f ¢oirferences 290,209 875.123 513,919 80,264 117,570 370,473 992,693 513,919 TotAI ¢xp¢nditure 1713 507 197834 Net Ineomt before Investment gatny anij tran5for5 1,045.892 1197.8341 848,058 NetgattL£ on insitnenis 620,772 620,772 Ntt ittcome net movements fund 1,666,664 1197,834) 1,468,830 RetoneiliAlioK of funds rund Wat￿￿5 ￿Oug￿ forward 9.284.692 620.715 9.905.407 balwK¢s ¢arriedforMgrd 18 10951356 422 881 11374237 All recognised gaÈns and losses are reflected Iknx)U￿ the StsleineDt of Financial ActivitÈes. All activities reflected above al'e contiliu￿g actiY*ties. 39 Regislercd cornpttny number.. 02645706